false--12-31Q220190001364099falseP1YP5YP5Y433100045460006880008520000.480.480.480.480.960.960.0010.0011000000001000000002298460823042492196130851969112400P20YP20YP20YP10YP7YP5YP5YP3Y34669000145990002803200013190003599100015870000309160001332000590000030000213000150003200000466000691000213000723000396600033715233351368 0001364099 2019-01-01 2019-06-30 0001364099 2019-08-02 0001364099 2019-06-30 0001364099 2018-12-31 0001364099 2019-04-01 2019-06-30 0001364099 2018-01-01 2018-06-30 0001364099 2018-04-01 2018-06-30 0001364099 2017-12-31 0001364099 2018-06-30 0001364099 us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001364099 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0001364099 us-gaap:AccountingStandardsUpdate201616Member 2018-01-01 2018-06-30 0001364099 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-06-30 0001364099 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001364099 us-gaap:CommonStockMember 2018-06-30 0001364099 iphs:AdditionalPaidinCapitalAndTreasuryStockMember 2018-01-01 2018-06-30 0001364099 us-gaap:CommonStockMember 2018-12-31 0001364099 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001364099 us-gaap:CommonStockMember 2017-12-31 0001364099 iphs:AdditionalPaidinCapitalAndTreasuryStockMember 2019-01-01 2019-06-30 0001364099 us-gaap:CommonStockMember 2019-06-30 0001364099 us-gaap:RetainedEarningsMember 2017-12-31 0001364099 us-gaap:RetainedEarningsMember 2018-12-31 0001364099 iphs:AdditionalPaidinCapitalAndTreasuryStockMember 2017-12-31 0001364099 us-gaap:AccountingStandardsUpdate201602Member us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001364099 iphs:AdditionalPaidinCapitalAndTreasuryStockMember 2018-06-30 0001364099 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0001364099 us-gaap:AccountingStandardsUpdate201616Member us-gaap:RetainedEarningsMember 2018-01-01 2018-06-30 0001364099 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001364099 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0001364099 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-06-30 0001364099 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001364099 us-gaap:RetainedEarningsMember 2018-06-30 0001364099 iphs:AdditionalPaidinCapitalAndTreasuryStockMember 2018-12-31 0001364099 us-gaap:RetainedEarningsMember 2019-06-30 0001364099 iphs:AdditionalPaidinCapitalAndTreasuryStockMember 2019-06-30 0001364099 us-gaap:CommonStockMember 2018-01-01 2018-06-30 0001364099 2018-02-01 2018-02-28 0001364099 2019-02-01 2019-02-28 0001364099 2018-05-01 2018-05-31 0001364099 2019-05-01 2019-05-31 0001364099 iphs:InventoryAndAOCIAdjustmentsMember 2019-04-01 2019-06-30 0001364099 iphs:InventoryAndAOCIAdjustmentsMember 2019-01-01 2019-06-30 0001364099 iphs:InventoryAndAOCIAdjustmentsMember 2018-01-01 2018-12-31 0001364099 iphs:InventoryAndAOCIAdjustmentsMember 2019-01-01 2019-03-31 0001364099 iphs:InventoryAndAOCIAdjustmentsMember 2019-06-30 0001364099 srt:ScenarioPreviouslyReportedMember 2018-01-01 2018-06-30 0001364099 srt:RestatementAdjustmentMember 2018-01-01 2018-06-30 0001364099 iphs:CoreIngredientsMember country:US 2019-04-01 2019-06-30 0001364099 iphs:SpecialtyIngredientsMember 2019-04-01 2019-06-30 0001364099 iphs:CoProductsAndOtherMember iphs:OtherForeignCountriesMember 2019-04-01 2019-06-30 0001364099 iphs:SpecialtyIngredientsMember iphs:OtherForeignCountriesMember 2019-04-01 2019-06-30 0001364099 iphs:SpecialtyIngredientsMember country:CA 2019-04-01 2019-06-30 0001364099 iphs:CoreIngredientsMember country:MX 2019-04-01 2019-06-30 0001364099 iphs:CoreIngredientsMember 2019-04-01 2019-06-30 0001364099 iphs:CoProductsAndOtherMember country:US 2019-04-01 2019-06-30 0001364099 iphs:OtherForeignCountriesMember 2019-04-01 2019-06-30 0001364099 iphs:CoreIngredientsMember iphs:OtherForeignCountriesMember 2019-04-01 2019-06-30 0001364099 country:CA 2019-04-01 2019-06-30 0001364099 country:MX 2019-04-01 2019-06-30 0001364099 country:US 2019-04-01 2019-06-30 0001364099 iphs:CoProductsAndOtherMember country:CA 2019-04-01 2019-06-30 0001364099 iphs:CoreIngredientsMember country:CA 2019-04-01 2019-06-30 0001364099 iphs:SpecialtyIngredientsMember country:MX 2019-04-01 2019-06-30 0001364099 iphs:SpecialtyIngredientsMember country:US 2019-04-01 2019-06-30 0001364099 iphs:CoProductsAndOtherMember 2019-04-01 2019-06-30 0001364099 iphs:CoProductsAndOtherMember country:MX 2019-04-01 2019-06-30 0001364099 iphs:SpecialtyIngredientsMember country:CA 2018-01-01 2018-06-30 0001364099 iphs:CoreIngredientsMember country:US 2018-01-01 2018-06-30 0001364099 iphs:CoProductsAndOtherMember country:US 2018-01-01 2018-06-30 0001364099 iphs:CoProductsAndOtherMember 2018-01-01 2018-06-30 0001364099 iphs:OtherForeignCountriesMember 2018-01-01 2018-06-30 0001364099 iphs:CoreIngredientsMember 2018-01-01 2018-06-30 0001364099 iphs:CoreIngredientsMember iphs:OtherForeignCountriesMember 2018-01-01 2018-06-30 0001364099 iphs:CoProductsAndOtherMember iphs:OtherForeignCountriesMember 2018-01-01 2018-06-30 0001364099 country:CA 2018-01-01 2018-06-30 0001364099 iphs:SpecialtyIngredientsMember iphs:OtherForeignCountriesMember 2018-01-01 2018-06-30 0001364099 iphs:CoreIngredientsMember country:MX 2018-01-01 2018-06-30 0001364099 country:MX 2018-01-01 2018-06-30 0001364099 iphs:SpecialtyIngredientsMember 2018-01-01 2018-06-30 0001364099 iphs:SpecialtyIngredientsMember country:MX 2018-01-01 2018-06-30 0001364099 iphs:CoreIngredientsMember country:CA 2018-01-01 2018-06-30 0001364099 country:US 2018-01-01 2018-06-30 0001364099 iphs:CoProductsAndOtherMember country:CA 2018-01-01 2018-06-30 0001364099 iphs:SpecialtyIngredientsMember country:US 2018-01-01 2018-06-30 0001364099 iphs:CoProductsAndOtherMember country:MX 2018-01-01 2018-06-30 0001364099 iphs:SpecialtyIngredientsMember country:MX 2018-04-01 2018-06-30 0001364099 iphs:SpecialtyIngredientsMember country:CA 2018-04-01 2018-06-30 0001364099 iphs:CoProductsAndOtherMember country:CA 2018-04-01 2018-06-30 0001364099 iphs:CoProductsAndOtherMember country:MX 2018-04-01 2018-06-30 0001364099 iphs:SpecialtyIngredientsMember country:US 2018-04-01 2018-06-30 0001364099 iphs:CoreIngredientsMember 2018-04-01 2018-06-30 0001364099 iphs:SpecialtyIngredientsMember 2018-04-01 2018-06-30 0001364099 iphs:SpecialtyIngredientsMember iphs:OtherForeignCountriesMember 2018-04-01 2018-06-30 0001364099 iphs:OtherForeignCountriesMember 2018-04-01 2018-06-30 0001364099 country:MX 2018-04-01 2018-06-30 0001364099 iphs:CoreIngredientsMember country:US 2018-04-01 2018-06-30 0001364099 country:US 2018-04-01 2018-06-30 0001364099 country:CA 2018-04-01 2018-06-30 0001364099 iphs:CoProductsAndOtherMember 2018-04-01 2018-06-30 0001364099 iphs:CoreIngredientsMember country:MX 2018-04-01 2018-06-30 0001364099 iphs:CoProductsAndOtherMember iphs:OtherForeignCountriesMember 2018-04-01 2018-06-30 0001364099 iphs:CoProductsAndOtherMember country:US 2018-04-01 2018-06-30 0001364099 iphs:CoreIngredientsMember country:CA 2018-04-01 2018-06-30 0001364099 iphs:CoreIngredientsMember iphs:OtherForeignCountriesMember 2018-04-01 2018-06-30 0001364099 iphs:SpecialtyIngredientsMember 2019-01-01 2019-06-30 0001364099 iphs:SpecialtyIngredientsMember country:MX 2019-01-01 2019-06-30 0001364099 iphs:CoreIngredientsMember iphs:OtherForeignCountriesMember 2019-01-01 2019-06-30 0001364099 iphs:CoreIngredientsMember country:CA 2019-01-01 2019-06-30 0001364099 iphs:SpecialtyIngredientsMember country:CA 2019-01-01 2019-06-30 0001364099 iphs:CoProductsAndOtherMember country:CA 2019-01-01 2019-06-30 0001364099 iphs:OtherForeignCountriesMember 2019-01-01 2019-06-30 0001364099 iphs:CoreIngredientsMember 2019-01-01 2019-06-30 0001364099 iphs:SpecialtyIngredientsMember country:US 2019-01-01 2019-06-30 0001364099 country:MX 2019-01-01 2019-06-30 0001364099 iphs:CoProductsAndOtherMember 2019-01-01 2019-06-30 0001364099 iphs:CoProductsAndOtherMember iphs:OtherForeignCountriesMember 2019-01-01 2019-06-30 0001364099 iphs:CoProductsAndOtherMember country:MX 2019-01-01 2019-06-30 0001364099 iphs:SpecialtyIngredientsMember iphs:OtherForeignCountriesMember 2019-01-01 2019-06-30 0001364099 iphs:CoreIngredientsMember country:MX 2019-01-01 2019-06-30 0001364099 country:US 2019-01-01 2019-06-30 0001364099 country:CA 2019-01-01 2019-06-30 0001364099 iphs:CoreIngredientsMember country:US 2019-01-01 2019-06-30 0001364099 iphs:CoProductsAndOtherMember country:US 2019-01-01 2019-06-30 0001364099 us-gaap:StockCompensationPlanMember 2018-01-01 2018-06-30 0001364099 us-gaap:PerformanceSharesMember 2018-04-01 2018-06-30 0001364099 us-gaap:RestrictedStockMember 2018-01-01 2018-06-30 0001364099 us-gaap:RestrictedStockMember 2019-01-01 2019-06-30 0001364099 us-gaap:PerformanceSharesMember 2019-04-01 2019-06-30 0001364099 us-gaap:StockCompensationPlanMember 2019-01-01 2019-06-30 0001364099 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0001364099 us-gaap:EmployeeStockOptionMember 2018-04-01 2018-06-30 0001364099 us-gaap:StockCompensationPlanMember 2019-04-01 2019-06-30 0001364099 us-gaap:RestrictedStockMember 2018-04-01 2018-06-30 0001364099 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-06-30 0001364099 us-gaap:PerformanceSharesMember 2019-01-01 2019-06-30 0001364099 us-gaap:StockCompensationPlanMember 2018-04-01 2018-06-30 0001364099 us-gaap:RestrictedStockMember 2019-04-01 2019-06-30 0001364099 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0001364099 us-gaap:PerformanceSharesMember 2018-01-01 2018-06-30 0001364099 iphs:FoodHealthandNutritionMember 2019-06-30 0001364099 iphs:IndustrialSpecialtiesMember 2019-06-30 0001364099 iphs:FoodHealthandNutritionMember 2018-12-31 0001364099 us-gaap:AllOtherSegmentsMember 2018-12-31 0001364099 iphs:IndustrialSpecialtiesMember 2018-12-31 0001364099 us-gaap:AllOtherSegmentsMember 2019-06-30 0001364099 2018-12-01 2018-12-31 0001364099 srt:MaximumMember 2019-01-01 2019-06-30 0001364099 2019-01-01 0001364099 us-gaap:SubsequentEventMember 2019-07-31 0001364099 iphs:CostofGoodsSoldMember 2019-01-01 2019-06-30 0001364099 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0001364099 iphs:CostofGoodsSoldMember 2019-04-01 2019-06-30 0001364099 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0001364099 srt:MinimumMember 2019-01-01 2019-06-30 0001364099 us-gaap:CustomerRelationshipsMember 2018-12-31 0001364099 us-gaap:CustomerRelationshipsMember 2019-06-30 0001364099 us-gaap:NoncompeteAgreementsMember 2018-12-31 0001364099 iphs:DevelopedTechnologyAndApplicationPatentsMember 2018-12-31 0001364099 iphs:DevelopedTechnologyAndApplicationPatentsMember 2019-06-30 0001364099 iphs:TradeNamesAndLicenseAgreementsMember 2019-06-30 0001364099 iphs:TradeNamesAndLicenseAgreementsMember 2018-12-31 0001364099 us-gaap:NoncompeteAgreementsMember 2019-06-30 0001364099 srt:MinimumMember iphs:DevelopedTechnologyAndApplicationPatentsMember 2019-01-01 2019-06-30 0001364099 srt:MaximumMember iphs:TradeNamesAndLicenseAgreementsMember 2019-01-01 2019-06-30 0001364099 srt:MinimumMember us-gaap:NoncompeteAgreementsMember 2019-01-01 2019-06-30 0001364099 srt:MaximumMember us-gaap:CustomerRelationshipsMember 2019-01-01 2019-06-30 0001364099 srt:MinimumMember iphs:TradeNamesAndLicenseAgreementsMember 2019-01-01 2019-06-30 0001364099 srt:MaximumMember us-gaap:NoncompeteAgreementsMember 2019-01-01 2019-06-30 0001364099 srt:MaximumMember iphs:DevelopedTechnologyAndApplicationPatentsMember 2019-01-01 2019-06-30 0001364099 srt:MinimumMember us-gaap:CustomerRelationshipsMember 2019-01-01 2019-06-30 0001364099 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2019-06-30 0001364099 us-gaap:LetterOfCreditMember us-gaap:LineOfCreditMember 2019-06-30 0001364099 us-gaap:BridgeLoanMember us-gaap:LineOfCreditMember 2019-06-30 0001364099 us-gaap:RevolvingCreditFacilityMember us-gaap:LineOfCreditMember 2018-12-31 0001364099 us-gaap:InterestRateSwapMember 2018-12-31 0001364099 us-gaap:LineOfCreditMember 2019-06-30 0001364099 iphs:InterestandDebtExpenseMember 2019-04-01 2019-06-30 0001364099 us-gaap:InterestRateSwapMember 2019-04-01 2019-06-30 0001364099 iphs:InterestandDebtExpenseMember 2018-01-01 2018-06-30 0001364099 iphs:InterestandDebtExpenseMember 2018-04-01 2018-06-30 0001364099 us-gaap:InterestRateSwapMember 2019-01-01 2019-06-30 0001364099 us-gaap:InterestRateSwapMember iphs:InterestandDebtExpenseMember 2019-01-01 2019-06-30 0001364099 us-gaap:InterestRateSwapMember 2018-01-01 2018-06-30 0001364099 us-gaap:InterestRateSwapMember iphs:InterestandDebtExpenseMember 2019-04-01 2019-06-30 0001364099 us-gaap:InterestRateSwapMember 2018-04-01 2018-06-30 0001364099 iphs:InterestandDebtExpenseMember 2019-01-01 2019-06-30 0001364099 us-gaap:InterestRateSwapMember iphs:InterestandDebtExpenseMember 2018-04-01 2018-06-30 0001364099 us-gaap:InterestRateSwapMember iphs:InterestandDebtExpenseMember 2018-01-01 2018-06-30 0001364099 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001364099 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001364099 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0001364099 us-gaap:OtherNoncurrentLiabilitiesMember us-gaap:InterestRateSwapMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-06-30 0001364099 iphs:NashvilleTNMember 2019-06-30 0001364099 srt:MaximumMember iphs:NashvilleTNMember 2019-06-30 0001364099 srt:MinimumMember iphs:NashvilleTNMember 2019-06-30 0001364099 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-06-30 0001364099 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-04-01 2018-06-30 0001364099 country:US 2018-01-01 2018-06-30 0001364099 country:US 2019-01-01 2019-06-30 0001364099 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-04-01 2018-06-30 0001364099 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-06-30 0001364099 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-06-30 0001364099 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-06-30 0001364099 country:US 2018-04-01 2018-06-30 0001364099 country:US us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-04-01 2019-06-30 0001364099 country:US 2019-04-01 2019-06-30 0001364099 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-04-01 2019-06-30 0001364099 country:US us-gaap:PensionPlansDefinedBenefitMember 2019-06-30 0001364099 country:CA us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-12-31 0001364099 country:CA us-gaap:PensionPlansDefinedBenefitMember 2019-06-30 0001364099 country:CA us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-01-01 2018-06-30 0001364099 country:CA 2019-04-01 2019-06-30 0001364099 country:CA us-gaap:PensionPlansDefinedBenefitMember 2019-04-01 2019-06-30 0001364099 country:CA us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2018-04-01 2018-06-30 0001364099 country:CA us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-01-01 2019-06-30 0001364099 country:CA 2019-01-01 2019-06-30 0001364099 country:CA 2018-04-01 2018-06-30 0001364099 country:CA us-gaap:PensionPlansDefinedBenefitMember 2018-04-01 2018-06-30 0001364099 country:CA us-gaap:PensionPlansDefinedBenefitMember 2019-01-01 2019-06-30 0001364099 country:CA 2018-01-01 2018-06-30 0001364099 country:CA us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember 2019-04-01 2019-06-30 0001364099 country:CA us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-06-30 0001364099 country:US us-gaap:PensionPlansDefinedBenefitMember 2018-01-01 2018-12-31 0001364099 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-04-01 2018-06-30 0001364099 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-01-01 2019-06-30 0001364099 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2017-12-31 0001364099 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-06-30 0001364099 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-04-01 2019-06-30 0001364099 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-06-30 0001364099 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-03-31 0001364099 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-06-30 0001364099 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-01-01 2018-06-30 0001364099 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-06-30 0001364099 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-03-31 0001364099 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-06-30 0001364099 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-04-01 2019-06-30 0001364099 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001364099 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-03-31 0001364099 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0001364099 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-06-30 0001364099 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001364099 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-04-01 2018-06-30 0001364099 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2019-03-31 0001364099 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0001364099 us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember 2018-12-31 0001364099 us-gaap:MaterialReconcilingItemsMember us-gaap:AllOtherSegmentsMember 2019-04-01 2019-06-30 0001364099 us-gaap:MaterialReconcilingItemsMember iphs:FoodHealthandNutritionMember 2019-04-01 2019-06-30 0001364099 us-gaap:MaterialReconcilingItemsMember iphs:IndustrialSpecialtiesMember 2019-04-01 2019-06-30 0001364099 us-gaap:AllOtherSegmentsMember 2019-01-01 2019-06-30 0001364099 us-gaap:AllOtherSegmentsMember 2018-04-01 2018-06-30 0001364099 us-gaap:AllOtherSegmentsMember 2019-04-01 2019-06-30 0001364099 iphs:FoodHealthandNutritionMember 2019-01-01 2019-06-30 0001364099 iphs:IndustrialSpecialtiesMember 2018-01-01 2018-06-30 0001364099 iphs:FoodHealthandNutritionMember 2019-04-01 2019-06-30 0001364099 iphs:IndustrialSpecialtiesMember 2019-04-01 2019-06-30 0001364099 iphs:FoodHealthandNutritionMember 2018-04-01 2018-06-30 0001364099 iphs:FoodHealthandNutritionMember 2018-01-01 2018-06-30 0001364099 iphs:IndustrialSpecialtiesMember 2018-04-01 2018-06-30 0001364099 us-gaap:AllOtherSegmentsMember 2018-01-01 2018-06-30 0001364099 iphs:IndustrialSpecialtiesMember 2019-01-01 2019-06-30 utreg:Rate xbrli:pure iphs:lease xbrli:shares iso4217:USD xbrli:shares iso4217:USD
Table of Contents

 
 
 
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 _______________________________________
FORM 10-Q
 ___________________________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2019

OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
 
For the transition period from              to               .
Commission File Number 001-33124
 ___________________________________________
INNOPHOS HOLDINGS, INC.
(Exact Name of Registrant as Specified in its Charter)
 ___________________________________________
 
Delaware
 
20-1380758
(State or Other Jurisdiction of
Incorporation or Organization)
 
(I.R.S. Employer
Identification No.)
 
 
259 Prospect Plains Road
Cranbury
New Jersey
08512
(Address of Principal Executive Offices)
 
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (609) 495-2495
 ____________________________________________
Securities registered pursuant to section 12(b) of the Act:
Title of each class
 
Trading symbol(s)
 
Name of exchange on which registered
Common Stock, $0.001 par value
 
IPHS
 
Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” "accelerated filer," “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer
 
Accelerated Filer
Non-accelerated filer
 
Smaller reporting company
 
 
 
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

Page 1 of 43



Table of Contents

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  
As of August 2, 2019, the registrant had 19,691,124 shares of common stock outstanding.
 

Page 2 of 43



Table of Contents

TABLE OF CONTENTS
 
 
 
Page
Financial Information
 
 
 
 
Item 1.
5
Item 2.
28
Item 3.
38
Item 4.
40
 
 
 
Other Information
 
 
 
 
Item 1.
41
Item 1A.
41
Item 2.
41
Item 3.
41
Item 4.
41
Item 5.
41
Item 6.
41
 
 
 
 
42

Page 3 of 43



Table of Contents

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
Unless the context requires otherwise, references to “Innophos,” “the Company,” “we,” “us” or “our” in this Quarterly Report on Form 10-Q refer to Innophos Holdings, Inc. and its consolidated subsidiaries.
This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” and/or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The forward-looking statements in this Quarterly Report on Form 10-Q may include, among other things, statements about: (1) global macroeconomic conditions and trends; (2) the behavior of financial markets, including fluctuations in foreign currencies, interest rates and turmoil in capital markets; (3) changes in regulatory controls regarding tariffs, duties, taxes and income tax rates; (4) our ability to implement and refine our Vision 2022 growth plan; (5) our ability to successfully identify and complete acquisitions in line with our Vision 2022 growth plan and effectively operate and integrate acquired businesses to realize the anticipated benefits of those acquisitions; (6) our ability to realize expected cost savings and efficiencies from our performance improvement and other optimization initiatives; (7) our ability to effectively compete in our markets, and to successfully develop new and competitive products that appeal to our customers; (8) changes in consumer preferences and demand for our products or a decline in consumer confidence and spending; (9) our ability to benefit from our investments in assets and human capital and the ability to complete projects successfully and on budget; (10) economic, regulatory and political risks associated with our international operations, most notably Mexico and China; (11) volatility and increases in the price of raw materials, energy and transportation, and fluctuations in the quality and availability of raw materials and process aids; (12) the impact of a disruption in our supply chain or our relationship with our suppliers; (13) our ability to comply with, and the costs associated with compliance with, U.S. and foreign environmental protection laws; (14) our ability to meet quality and regulatory standards in the various jurisdictions in which we have operations or conduct business; and (15) other information that is not historical information.
You should refer to “Part I, Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on February 27, 2019, for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements.  As a result of these factors, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete discussion of all potential risks or uncertainties that may substantially impact our business. Moreover, we operate in a competitive and rapidly changing environment. New factors emerge from time to time and it is not possible to predict the impact of all of these factors on our business, financial condition or results of operations.
Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
You should read this Quarterly Report on Form 10-Q and any documents that we reference in this report completely and with the understanding that our actual future results may be materially different from what we expect. We qualify all of our forward-looking statements by these cautionary statements.

Page 4 of 43



Table of Contents

PART I - FINANCIAL INFORMATION
 
ITEM 1.
FINANCIAL STATEMENTS
INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Balance Sheets (Unaudited)
(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)
 
 
June 30,
2019
 
December 31,
2018
ASSETS
 
 
 
Current assets:
 
 
 
Cash and cash equivalents
$
32,040

 
$
20,197

Accounts receivable, net of allowance for doubtful accounts ($852 and $688)
98,957

 
102,564

Inventories
172,455

 
180,203

Other current assets
37,012

 
24,094

Total current assets
340,464

 
327,058

Property, plant and equipment, net
235,349

 
240,235

Lease right-of-use assets
51,604

 

Goodwill
152,767

 
152,767

Intangibles and other assets, net
89,971

 
95,094

Total assets
$
870,155

 
$
815,154

LIABILITIES AND STOCKHOLDERS' EQUITY
 
 
 
Current liabilities:
 
 
 
Accounts payable, trade and other
$
51,297

 
$
80,007

Other current liabilities
67,993

 
49,993

Total current liabilities
119,290

 
130,000

Long-term debt
330,000

 
300,000

Long-term lease liabilities
45,478

 

Other long-term liabilities
36,200

 
49,639

Total liabilities
$
530,968

 
$
479,639

Commitments and contingencies (Note 14)


 


Common stock, par value $.001 per share; authorized 100,000,000; issued 23,042,492 and 22,984,608; outstanding 19,691,124 and 19,613,085 shares
$
20

 
$
20

Paid-in capital
146,107

 
142,558

Common stock held in treasury, at cost (3,351,368 and 3,371,523 shares)
(177,097
)
 
(176,862
)
Retained earnings
375,960

 
372,815

Accumulated other comprehensive loss
(5,803
)
 
(3,016
)
Total stockholders' equity
339,187

 
335,515

Total liabilities and stockholders' equity
$
870,155

 
$
815,154


See notes to condensed consolidated financial statements

Page 5 of 43



Table of Contents

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Comprehensive Income (Unaudited)
(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)
 
 
Three months ended
 
Six months ended
 
June 30,
2019
 
June 30,
2018
 
June 30,
2019
 
June 30,
2018
Net sales
$
185,038

 
$
206,725

 
$
376,452

 
$
412,165

Cost of goods sold
148,646

 
170,340

 
303,648

 
333,553

Gross profit
36,392

 
36,385

 
72,804

 
78,612

Operating expenses:
 
 
 
 
 
 
 
Selling, general and administrative
20,261

 
22,503

 
39,703

 
45,023

Research & development expenses
1,232

 
1,338

 
2,572

 
2,749

Total operating expenses
21,493

 
23,841

 
42,275

 
47,772

Operating income
14,899

 
12,544

 
30,529

 
30,840

Interest expense, net
3,887

 
3,198

 
7,589

 
6,102

Foreign exchange (gain) loss
(470
)
 
1,136

 
(851
)
 
940

Other (income), net
(8
)
 
(13
)
 
(11
)
 
(28
)
Income before income taxes
11,490

 
8,223

 
23,802

 
23,826

Provision for income taxes
10,089

 
1,977

 
13,707

 
6,665

Net income
$
1,401

 
$
6,246

 
$
10,095

 
$
17,161

Net income attributable to participating common shareholders
$
1,381

 
$
6,213

 
$
10,057

 
$
17,106

 
 
 
 
 
 
 
 
Per share data (Note 3):
 
 
 
 
 
 
 
Income per participating share:
 
 
 
 
 
 
 
Basic
$
0.07

 
$
0.32

 
$
0.51

 
$
0.88

Diluted
$
0.07

 
$
0.31

 
$
0.51

 
$
0.87

Weighted average participating shares outstanding:
 
 
 
 
 
 
 
Basic
19,572,648

 
19,505,877

 
19,571,742

 
19,503,755

Diluted
19,776,845

 
19,818,883

 
19,715,907

 
19,765,971

 
 
 
 
 
 
 
 
Other comprehensive income (loss), net of tax:
 
 
 
 
 
 
 
Change in interest rate swaps, (net of tax of $466, $0, $691, and $0)
$
(1,397
)
 
$

 
$
(2,073
)
 
$

Change in pension and post-retirement plans, (net of tax of $15, ($30), $32, and $213)
(662
)
 
94

 
(714
)
 
483

Other comprehensive income (loss), net of tax
$
(2,059
)
 
$
94

 
$
(2,787
)
 
$
483

Comprehensive (loss) income
$
(658
)
 
$
6,340

 
$
7,308

 
$
17,644


See notes to condensed consolidated financial statements

Page 6 of 43



Table of Contents

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Condensed Consolidated Statements of Cash Flows (Unaudited)
(Dollars in thousands)
 
 
Six months ended
 
June 30,
2019
 
June 30,
2018
Cash flows provided by operating activities
 
 
 
Net income
$
10,095

 
$
17,161

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation and amortization
20,646

 
22,453

Amortization of deferred financing charges
215

 
215

Deferred income tax provision

208

 
97

Dutch income tax liability
6,603

 

Share-based compensation
3,567

 
2,992

Changes in assets and liabilities:
 
 
 
Accounts receivable
3,607

 
(8,110
)
Inventories
7,748

 
(13,136
)
Other current assets
(12,918
)
 
(4,481
)
Accounts payable
(24,129
)
 
(2,692
)
Other current liabilities
4,226

 
(718
)
Other long-term assets and liabilities, net
(3,087
)
 
(4,224
)
Net cash provided by operating activities
16,781

 
9,557

Cash flows used for investing activities:
 
 
 
Capital expenditures
(15,837
)
 
(26,475
)
Net cash used for investing activities
(15,837
)
 
(26,475
)
Cash flows provided by financing activities:
 
 
 
Long-term debt borrowings
37,000

 
61,000

Long-term debt repayments
(7,000
)
 
(41,000
)
Restricted stock forfeitures
(235
)
 
(251
)
Dividends paid
(18,866
)
 
(18,782
)
Net cash provided by financing activities
10,899

 
967

Effect of foreign exchange rate changes on cash and cash equivalents

 
(559
)
Net change in cash
11,843

 
(16,510
)
Cash and cash equivalents at beginning of period
20,197

 
28,782

Cash and cash equivalents at end of period
$
32,040

 
$
12,272

 
 
 
 
Supplemental disclosures of cash flow information:
 
 
 
Non-cash investing and financing activities:
 
 
 
Accrued additions to plant assets
$
4,824

 
$
12,121


See notes to condensed consolidated financial statements

Page 7 of 43



Table of Contents

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Statement of Stockholders’ Equity (Unaudited)
(Dollars and shares in thousands)
 
Number of
Common
Shares
 
Common
Stock
 
Retained
Earnings (Deficit)
 
Paid-in
Capital / Common stock held in treasury
 
Accumulated
Other
Comprehensive
Income/(Loss)
 
Total
Shareholders'
Equity
Balance, December 31, 2017
19,538

 
$
20

 
$
374,366

 
$
(38,629
)
 
$
(2,198
)
 
$
333,559

Net income
 
 
 
 
17,161

 
 
 
 
 
17,161

Other comprehensive income, (net of tax $213) (a)
 
 
 
 
 
 
 
 
483

 
483

Effects of U.S. enacted Tax Cuts and Jobs Act (a)
 
 
 
 
(293
)
 
 
 
 
 
(293
)
Effects of adoption of ASU 2016-16, Income Taxes (Topic 740): Intra-Entity Transfers of Assets Other Than Inventory
 
 
 
 
360

 
 
 
 
 
360

Equity-based compensation
68

 
 
 
 
 
2,535

 
 
 
2,535

Dividends declared ($0.96 per share) (b)
 
 
 
 
(18,835
)
 
 
 
 
 
(18,835
)
Balance, June 30, 2018
19,606

 
$
20

 
$
372,759

 
$
(36,094
)
 
$
(1,715
)
 
$
334,970

 
 
 
 
 
 
 
 
 
 
 
 
Balance, December 31, 2018
19,613

 
$
20

 
$
372,815

 
$
(34,304
)
 
$
(3,016
)
 
$
335,515

Net income
 
 
 
 
10,095

 
 
 
 
 
10,095

Other comprehensive loss, (net of tax $723)
 
 
 
 
 
 
 
 
(2,787
)
 
(2,787
)
Effects of adoption of ASC 842 (net of tax $3,966) (c)
 
 
 
 
11,897

 
 
 
 
 
11,897

Equity-based compensation plans
78

 
 
 
 
 
3,314

 
 
 
3,314

Dividends declared ($0.96 per share) (d)
 
 
 
 
(18,847
)
 
 
 
 
 
(18,847
)
Balance, June 30, 2019
19,691

 
$
20

 
$
375,960

 
$
(30,990
)
 
$
(5,803
)
 
$
339,187

(a) Includes the impact of ASU 2018-02, which transferred those amounts from accumulated other comprehensive income (loss) to retained earnings. See Note 16 to the Condensed Consolidated Financial Statements.
(b) $0.48 per share declared February 2018 and May 2018
(c) On the transition to ASC 842 effective January 1, 2019, a deferred gain (net of taxes) related to a sale leaseback transaction was credited to Retained Earnings. See Note 8 to the Condensed Consolidated Financial Statements.
(d) $0.48 per share declared February 2019 and April 2019


See notes to condensed consolidated financial statements

Page 8 of 43



Table of Contents

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)

1. Basis of Statement Presentation
Summary of Significant Accounting Policies
The accompanying unaudited condensed consolidated financial statements of Innophos have been prepared in accordance with generally accepted accounting principles in the United States of America, or U.S. GAAP, for interim financial reporting and do not include all disclosures required by U.S. GAAP for annual financial reporting, and should be read in conjunction with the audited consolidated and combined financial statements of the Company at December 31, 2018 and for the three years then ended.
The accompanying unaudited condensed consolidated financial statements of the Company reflect all adjustments which management considers necessary for a fair statement of the results of operations for the interim periods and is subject to year-end adjustments. The results of operations for the interim periods are not necessarily indicative of the results for the full year. The December 31, 2018 condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by U.S. GAAP.
Error Correction 

During the fourth quarter of 2018, the Company identified an error associated with disclosing 2018 accrued capital expenditures and adjusting for them as non-cash investing activities in the Condensed Consolidated Statements of Cash Flows. The Company has evaluated the materiality of the error and concluded it was not material to any of the previously issued consolidated financial statements. However, the Company has elected to revise its consolidated cash flow statement for the period ending June 30, 2018 to correct the error.

The following table presents the effect of the revision on the selected line items previously reported in the consolidated cash flows statement for the six months ended June 30, 2018:
 
June 30, 2018
 
 
 
June 30, 2018
Consolidated Statement of Cash Flows
As reported
 
Adjustment
 
As revised
Cash flows from operating activities
 
 
 
 
 
Changes in assets and liabilities:
 
 
 
 
 
Accounts payable
$
(141
)
 
$
(2,551
)
 
$
(2,692
)
Net cash provided by (used for) operations
$
12,108

 
$
(2,551
)
 
$
9,557

 
 
 
 
 
 
Cash flows used for investing activities
 
 
 
 
 
Capital expenditures
$
(29,026
)
 
$
2,551

 
$
(26,475
)
Net cash (used for) investing activities
$
(29,026
)
 
$
2,551

 
$
(26,475
)
 
 
 
 
 
 
Supplemental disclosures of cash flow information:
 
 
 
 
 
Non-cash investing and financing activities
 
 
 
 
 
Accrued additions to plant assets
 
 
$
12,121

 
$
12,121



These accompanying notes to the consolidated financial statements reflect the impact of this revision. The revision of the Company’s interim Condensed Consolidated Statements of Cash Flows in the previously issued unaudited condensed consolidated financial statements for the nine months ended September 30, 2018 will be effected in connection with the Company’s filing of its Form 10-Q for the quarter ended September 30, 2019.

During the second quarter of 2019, the Company identified and corrected errors related to the valuation of its inventory located at one of its domestic subsidiaries and the translation of Accumulated other comprehensive income (loss) related to pension and post retirement obligations at a foreign subsidiary. The adjustments decreased Cost of goods sold by $3.1 million and Foreign exchange (gain) loss by $0.7 million resulting in an increase to income before income taxes of approximately $3.8 million in the three month period ended June 30, 2019 and increased the Inventory balance by $3.1 million and decreased Accumulated other comprehensive income before income taxes by $0.7 million as of June 30, 2019.

Page 9 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Approximately $1.2 million of the cumulative adjustment should have been recorded during the first quarter of 2019 and the remaining $2.6 million related to prior periods. Management has concluded that these adjustments are not material to the periods presented or any of its previously issued financial statements, and are not expected to be material to the full year 2019 results.
Recently Issued Accounting Standards
Adopted
In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), in order to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet for those leases classified as operating leases under previous GAAP. ASU 2016-02 requires that a lessee should recognize a liability to make lease payments (the lease liability) and a right-of-use asset (ROU asset) representing its right to use the underlying asset for the lease term on the balance sheet. ASU 2016-02 is effective for fiscal years beginning after December 15, 2018 (including interim periods within those periods) using a modified retrospective approach and early adoption is permitted. In July 2018, the FASB issued updated guidance which allows an additional transition method to adopt the new leases standard at the adoption date, as compared to the beginning of the earliest period presented, and recognize a cumulative-effect adjustment to the beginning balance of retained earnings in the period of adoption (the effective date method). The Company adopted this standard as of January 1, 2019, and has elected the effective date method. The Company also elected the package of practical expedients, which among other things, does not require reassessment of prior conclusions to contracts containing a lease, lease classification, and initial direct costs. As an accounting policy election, the Company will exclude short-term leases (term of 12 months or less) from the balance sheet. The Company's lease agreements do not contain any residual value guarantees. Please see Note 8, "Leases", for further disclosures.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and hedging (Topic 815): Targeted improvements to accounting for hedging activities. This standard more closely aligns the results of cash flow and fair value hedge accounting with risk management activities through changes to both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results in the financial statements. This standard also addresses specific limitations in current GAAP by expanding hedge accounting for both nonfinancial and financial risk components and by refining the measurement of hedge results to better reflect an entity’s hedging strategies. Additionally, by aligning the timing of recognition of hedge results with the earnings effect of the hedged item for cash flow and net investment hedges, and by including the earnings effect of the hedging instrument in the same income statement line item in which the earnings effect of the hedged item is presented, the results of an entity’s hedging program and the cost of executing that program will be more visible to users of financial statements. The new standard is effective for annual reporting periods beginning after December 15, 2018 with early adoption permitted. The Company adopted this standard on January 1, 2019, and there was no material impact on its financial position, results of operations and related disclosures.
Issued but not yet adopted
In August 2018, the FASB issued ASU No. 2018-14, Compensation - Retirement Benefits - Defined Benefit Plans - General (Topic 715-20), Disclosure Framework - Changes to the Disclosure Requirements for Defined Benefit Plans. This amendment modifies the disclosure requirements for employers that sponsor defined benefit pension or other postretirement plans by removing and adding certain disclosures for these plans. The eliminated disclosures include the amounts in accumulated other comprehensive income expected to be recognized in net periodic benefit costs over the next fiscal year and the effects of a one-percentage-point change in assumed health care cost trend rates on the net periodic benefit costs and the benefit obligation for postretirement health care benefits. New disclosures include the interest crediting rates for cash balance plans, and an explanation of significant gains and losses related to changes in benefit obligations. The new standard is effective for fiscal years beginning after December 15, 2020, and must be applied retrospectively for all periods presented. Early adoption is permitted. The Company does not anticipate the adoption of this standard will have a material impact on its financial position, results of operations and related disclosures.

2. Revenue Recognition
Revenues are recognized when control of goods is transferred to customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods. Control passes either upon shipment or delivery, depending on the agreed sales terms with customers.

Page 10 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


Certain customers may receive cash-based incentives or credits, which are accounted for as variable consideration. The Company estimates these amounts based on the expected amount to be provided to customers and reduce revenues recognized. There were no significant changes to its estimates of variable consideration upon adoption.

The Company reports its business in three operating segments: Food, Health, and Nutrition; Industrial Specialties; and Other. The Company has three principal product lines within these operating segments: (i) Specialty Ingredients; (ii) Core Ingredients; and (iii) Co-Products and Other. Revenue recognition is measured on the same basis across these segments, products, markets, and geographic countries, with the performance obligation being the transfer of control of goods at a single point in time.


 
Three Months Ended June 30, 2019
 
U.S.
 
Canada
 
Mexico
 
Other Countries
 
Total
Specialty Ingredients
$
93,335

 
$
3,899

 
$
9,034

 
$
19,700

 
$
125,968

Core Ingredients
15,982

 
2,444

 
23,369

 
6,656

 
48,451

Co-Products & Other
5,395

 
73

 
4,939

 
212

 
10,619

Total
$
114,712

 
$
6,416

 
$
37,342

 
$
26,568

 
$
185,038


 
Three Months Ended June 30, 2018
 
U.S.
 
Canada
 
Mexico
 
Other Countries
 
Total
Specialty Ingredients
$
112,614

 
$
6,441

 
$
9,101

 
$
20,425

 
$
148,581

Core Ingredients
12,274

 
2,244

 
22,339

 
9,456

 
46,313

Co-Products & Other
5,488

 
68

 
5,849

 
426

 
11,831

Total
$
130,376

 
$
8,753

 
$
37,289

 
$
30,307

 
$
206,725


 
Six Months Ended June 30, 2019
 
U.S.
 
Canada
 
Mexico
 
Other Countries
 
Total
Specialty Ingredients
$
193,863

 
$
9,177

 
$
17,466

 
$
39,378

 
$
259,884

Core Ingredients
31,068

 
4,695

 
45,978

 
11,471

 
93,212

Co-Products & Other
17,766

 
219

 
5,088

 
283

 
23,356

Total
$
242,697

 
$
14,091

 
$
68,532

 
$
51,132

 
$
376,452



 
Six Months Ended June 30, 2018
 
U.S.
 
Canada
 
Mexico
 
Other Countries
 
Total
Specialty Ingredients
$
227,398

 
$
12,279

 
$
16,718

 
$
39,829

 
$
296,224

Core Ingredients
28,689

 
4,244

 
39,982

 
19,214

 
92,129

Co-Products & Other
14,195

 
133

 
9,057

 
427

 
23,812

Total
$
270,282

 
$
16,656

 
$
65,757

 
$
59,470

 
$
412,165



Revenues for the geographic information are attributed to geographic areas based on the destination of the sale.
The Company's payment terms vary by geography and location of its customer and the products offered. Invoices are generated upon shipment of the goods, with the term between invoicing and when payment is due being insignificant.


Page 11 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Food, Health, and Nutrition and Industrial Specialties
The Food, Health and Nutrition reporting segment, as well as the Industrial Specialties reporting segment, consists of products in the Specialty Ingredients and Core Ingredients product lines.

Specialty Ingredients are the most value adding products in our portfolio. Specialty Ingredients consist of specialty phosphate products, specialty phosphoric acids, including polyphosphoric acid, and a range of other mineral, enzyme and botanical based specialty ingredients. The Company's Specialty Ingredients products have a wide range of applications, including:
flavor enhancers in beverages;
electrolytes in sports drinks;
texture modifiers in cheeses;
leavening agents in baked goods;
calcium and phosphorus fortification in food and beverages;
moisture and color retention in seafood, poultry and meat;
mineral, enzyme and botanical sources for a wide variety of fortified foods, beverages and dietary supplements;
excipients in vitamins, minerals, nutritional supplements and pharmaceuticals; and
abrasives in toothpaste.

Each product typically has a number of different applications and end uses. For example, the Company's dicalcium phosphate product can be used as an excipient for pharmaceutical and dietary supplements, a leavening agent in bakery products and as an abrasive in oral care products. The Company often works directly with customers to tailor products to their required specifications for their finished product application.

The Company's Core Ingredients product line includes food grade purified phosphoric acid, or PPA, technical grade PPA, sodium tripolyphosphate, or STPP, and detergent grade PPA. Food grade PPA can be used to produce phosphate salts and has a variety of applications in food and beverages. Technical grade PPA has applications in water treatment. The Company also sells technical grade PPA in the merchant market to third-party phosphate derivative producers. STPP is a key ingredient in cleaning products, including industrial and institutional cleaners and automatic dishwashing detergents and consumer laundry detergents outside the United States. In addition to its use in cleaning products, STPP is also used in water treatment, clay processing, and copper ore processing. The end use market for STPP is largely derived from consumer product applications. Detergent Grade PPA is a lower grade form of PPA used primarily in the production of STPP.
Other
The Other reporting segment consists of products in the Co-Products and Other product line.
The Company's Co-Products and Other product line includes granular triple super phosphate, or GTSP, and merchant green phosphoric acid, or MGA. GTSP is generated at the Company's Coatzacoalcos facility in Mexico as a co-product of its purified wet acid manufacturing process. GTSP is a fertilizer product used throughout Latin America for increasing crop yields in a wide range of agricultural sectors. The Company sells MGA in the merchant market to third party manufacturers of fertilizer products.

Practical Expedients and Exemptions

Management reviewed the practical expedients which a Company may utilize when implementing Topic 606 - Revenue from Contracts with Customers. As such, the Company has applied the practical expedient related to significant financing components and does not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less.

3. Earnings per Share (EPS)

The Company accounts for earnings per share in accordance with ASC 260 and related guidance, which requires two calculations of earnings per share (EPS) to be disclosed: basic EPS and diluted EPS. Under ASC Subtopic 260-10-45, as of January 1, 2009 unvested awards of share-based payments with rights to receive dividends or dividend equivalents, such as restricted stock, are considered participating securities for purposes of calculating EPS. Under the two-class method, a portion

Page 12 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

of net income is allocated to these participating securities and therefore is excluded from the calculation of EPS allocated to common stock, as shown in the table below.

The numerator for basic and diluted earnings per share is net earnings attributable to shareholders reduced by dividends attributable to unvested shares. The denominator for basic earnings per share is the weighted average number of common stock outstanding during the period. The denominator for diluted earnings per share is weighted average shares outstanding adjusted for the effect of dilutive outstanding stock options, performance share awards and restricted stock awards.
    
The following is a reconciliation of the weighted average basic number of common shares outstanding to the diluted number of common and common stock equivalent shares outstanding and the calculation of earnings per share using the two-class method:

 
 
Three Months Ended
 
Six Months Ended
 
June 30, 2019
 
June 30, 2018
 
June 30, 2019
 
June 30, 2018
Net income
$
1,401

 
$
6,246

 
$
10,095

 
$
17,161

Less: earnings attributable to unvested shares
(20
)
 
(33
)
 
(38
)
 
(55
)
Net income available to participating common shareholders
$
1,381

 
$
6,213

 
$
10,057

 
$
17,106

Weighted average number of participating common and potential common shares outstanding:
 
 
 
 
 
 
 
Basic number of participating common shares outstanding
19,572,648

 
19,505,877

 
19,571,742

 
19,503,755

Dilutive effect of stock equivalents
204,197

 
313,006

 
144,165

 
262,216

Diluted number of weighted average participating common shares outstanding
19,776,845

 
19,818,883

 
19,715,907

 
19,765,971

Earnings per participating common share:
 
 
 
 
 
 
 
Earnings per participating common share—Basic
$
0.07

 
$
0.32

 
$
0.51

 
$
0.88

Earnings per participating common share—Diluted
$
0.07

 
$
0.31

 
$
0.51

 
$
0.87

 
 
 
 
 
 
 
 
Total outstanding options, performance share awards and unvested restricted stock not included in the calculation of diluted earnings per share as the effect would be anti-dilutive
867,092

 
468,773

 
924,886

 
519,563




Page 13 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


4. Stockholders’ Equity / Share-Based Compensation
The following table summarizes the components of share-based compensation expense, all of which has been classified as selling, general and administrative expense:
 
 
Three Months Ended
 
Six Months Ended
 
June 30,
2019
 
June 30,
2018
 
June 30,
2019
 
June 30,
2018
Stock options
$
485

 
$
538

 
$
802

 
$
884

Restricted stock
745

 
755

 
1,272

 
1,280

Performance shares
850

 
122

 
793

 
249

Stock grants
700

 
579

 
700

 
579

Total share-based compensation expense
$
2,780

 
$
1,994

 
$
3,567

 
$
2,992



5. Inventories
Inventories consist of the following:
 
 
June 30,
2019
 
December 31,
2018
Raw materials
$
43,018

 
$
46,147

Finished products (a)
114,293

 
119,407

Spare parts
15,144

 
14,649

 
$
172,455

 
$
180,203



(a) The balance as of June 30, 2019 includes a $3.1 million increase related to a cumulative adjustment of capitalized variances.

Inventory reserves for excess quantities, obsolescence or shelf-life expiration as of June 30, 2019 and December 31, 2018 were $16,490 and $14,327, respectively.



Page 14 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)



6. Other Current Assets
Other current assets consist of the following:
 
 
June 30,
2019
 
December 31,
2018
Creditable taxes (value added taxes)
$
14,405

 
$
11,944

Vendor inventory deposits (prepaid)
3,108

 
454

Prepaid income taxes
16,461

 
6,658

Prepaid insurance
797

 
2,605

Other
2,241

 
2,433

 
$
37,012

 
$
24,094




7. Goodwill

The following table provides a reconciliation of the carrying amount of goodwill at the beginning and end of the reporting period (in thousands):

 
Food, Health and Nutrition
Industrial Specialties
Other
Total
Balance: January 1, 2019
$
129,484

$
23,283

$

$
152,767

Balance: June 30, 2019
$
129,484

$
23,283

$

$
152,767




8. Leases

The Company determines if an arrangement is a lease at inception. Lease Right of Use, or ROU, assets and noncurrent lease liabilities are presented as distinct accounts in the Condensed Consolidated Balance Sheet. Current lease liabilities are included within Other current liabilities in the Condensed Consolidated Balance Sheet. The Company does not have any Finance leases. ROU assets represent the right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the lease term. The Company uses its estimated incremental borrowing rate, which is derived from information available at the lease commencement date, in determining the present value of lease payments, as the implicit rate is not readily determinable. The Company gives consideration to publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates. The lease term includes options to extend the lease when it is reasonably certain that the Company will exercise that option. Leases with a term of 12 months or less are not recorded on the balance sheet. Certain leases include one or more options to renew, with renewal terms that can extend the lease up to five years and certain leases also include options to purchase the leased property. We include options that we are reasonably certain to exercise in our evaluation of the lease term after considering all relevant economic and financial factors. We have lease agreements with lease and non-lease components, which are generally accounted for as a single lease component.

The Company primarily leases rail cars, inventory tanks, buildings, equipment, and fleet cars. The Company recorded ROU assets of $48.8 million and lease liabilities of $48.9 million, respectively at January 1, 2019. The impact to the Company's Condensed Consolidated Statement of Comprehensive Income and Condensed Consolidated Statement of Cash Flows was not material. As of June 30, 2019, the Company had 43 leases, with remaining terms ranging from less than one year to 20 years.

Under one of its warehousing agreements with third-party service providers, the Company controls the amount, timing, placing, and removing of items for the entire capacity of the warehouse. Therefore the Company controls the asset, and

Page 15 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

the warehouse is deemed to be leased for accounting purposes. For this warehousing agreement, the Company accounts for the lease and non-lease components separately. The lease component consists of the warehouse and the non-lease components consist of services, such as loading, unloading, and maintenance. The Company allocates the consideration in the warehousing agreement to the lease and non-lease components using their relative standalone prices.
    
In December 2018, the Company sold its Chicago Heights, IL warehouse for $23.0 million. Under the agreement, the Company is leasing back the property from the purchaser over a period of 20 years. The Company is accounting for the leaseback as an operating lease. The annual rent for the initial period of five years is approximately $1.5 million plus taxes and subsequently will increase 10% every five years through the end of the lease. Prior to the adoption of the new lease standard, gains on sale-leaseback transactions were deferred and recognized in the statement of comprehensive income over the lease term. Under the new lease standard, gains on sale-leaseback transactions (subject to adjustment for off-market terms) are recognized immediately. Therefore, the sale-leaseback gain of $11.9 million (net of tax of $4.0 million) was deferred as of December 31, 2018 and on the transition to ASC 842 effective January 1, 2019, was reclassed to retained earnings.
    
The components of lease expense were as follows:
 
Three months ended
 
Six months ended
 
June 30, 2019
 
June 30, 2019
Operating lease expense:
 
 
 
Cost of goods sold
$
1,556

 
$
2,992

Selling, general and administrative
941

 
1,808

Total lease expense
$
2,497

 
$
4,800



Supplemental balance sheet information related to the leases were as follows:
 
June 30, 2019
Operating lease ROU assets
$
51,604

 
 
Current operating lease liabilities
$
6,328

Noncurrent operating lease liabilities
45,478

Total operating lease liabilities
$
51,806



Supplemental cash flow and other information related to the leases were as follows:
 
Six months ended
 
June 30, 2019
Cash paid for amounts included in the measurement of operating lease liabilities
$
4,694

ROU assets obtained in exchange for new operating lease liabilities
$
6,230


 
June 30, 2019
Weighted average remaining lease term of operating leases (in years)
11

Weighted average discount rate of operating leases
5.35
%



Page 16 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


Maturities of lease liabilities were as follows:
 
June 30, 2019
2019
$
4,742

2020
8,140

2021
7,320

2022
6,793

2023
6,175

2024 and thereafter
38,195

Total lease payments
$
71,365

Less: imputed interest
19,559

Total lease obligations
$
51,806

Less: current obligations
6,328

Long-term lease obligations
$
45,478



As required by ASC 842, the future minimum operating lease payments on non-cancelable leases as of December 31, 2018 under the accounting standards in effect as of that period were as follows:
 
December 31, 2018
2019
$
8,259

2020
7,130

2021
6,490

2022
6,032

2023
5,467

2024 and thereafter
33,957

Long-term lease obligations
$
67,335



In July 2019, the Company executed an agreement to exercise its option to renew the lease on its Cranbury, NJ headquarters for a period of five years beginning January 1, 2020. The Company will account for this lease modification as a change in lease term. The Company will remeasure the lease obligation and related ROU asset in July 2019, which will result in an increase in each account of approximately $5.9 million.


Page 17 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

9. Intangibles and Other Assets, net
Intangibles and other assets consist of the following:
 
 
Useful life
(years)
 
June 30,
2019
 
December 31,
2018
Developed technology and application patents, net of accumulated amortization of $35,991 for 2019 and $34,669 for 2018
7-20
 
$
10,284

 
$
11,606

Customer relationships, net of accumulated amortization of $30,916 for 2019 and $28,032 for 2018
5-20
 
64,597

 
67,479

Trade names and license agreements, net of accumulated amortization of $15,870 for 2019 and $14,599 for 2018
5-20
 
11,691

 
12,962

Non-compete agreements, net of accumulated amortization of $1,332 for 2019 and $1,319 for 2018
3-10
 
1

 
14

Total intangibles, net
 
 
$
86,573

 
$
92,061

Deferred financing costs, net of accumulated amortization of $4,546 for 2019 and $4,331 for 2018 (see Note 11)
 
 
$
1,076

 
$
1,291

Other assets
 
 
2,322

 
1,742

Total other assets, net
 
 
$
3,398

 
$
3,033

 
 
 
$
89,971

 
$
95,094



Page 18 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)



10. Other Current Liabilities
Other current liabilities consist of the following:
 
 
June 30,
2019
 
December 31,
2018
Payroll related
$
14,342

 
$
15,656

Operating lease liabilities
6,328

 

Taxes other than income taxes
1,841

 
3,071

Benefits and pensions
5,257

 
5,680

Freight and rebates
3,759

 
6,431

Income taxes
15,516

 
1,355

Restructuring reserve

 
217

Deferred gain on sale leaseback transaction (a)

 
790

Deferred contract termination (b)
9,623

 
9,489

Other
11,327

 
7,304

 
$
67,993

 
$
49,993


(a) See Note 8 to the Consolidated Financial Statements for further details.
(b) See Note 18 to the Consolidated Financial Statements for further details.

11. Short-Term Borrowings, Long-Term Debt, and Interest Expense
Short-term borrowings and long-term debt consist of the following:
 
 
June 30,
2019
 
December 31,
2018
Revolver borrowings under the credit facility due 2021
$
330,000

 
$
300,000

Long-term debt
$
330,000

 
$
300,000



The Company's credit facility includes a revolving line of credit from the lenders of up to $450.0 million, including a $20.0 million letter of credit sub-facility and a $20.0 million swingline loan facility, all maturing on December 22, 2021. The credit agreement governing this facility also provides for possible additional revolving indebtedness under an incremental facility of up to $150.0 million (for an aggregate of revolving capacity up to $600.0 million) upon future request by the Company to existing lenders (and depending on their consent) or from other willing financial institutions invited by the Company and reasonably acceptable to the administrative agent to join in the credit agreement. This revolving credit facility increase, if implemented, may provide for higher applicable margins to either the increased portion or possibly the entire revolving credit facility, with limitations, than those in effect for the original revolving commitments under the credit agreement.
As of June 30, 2019, $330.0 million was outstanding under the revolving line of credit, which approximates fair value (determined using level 2 inputs within the fair value hierarchy) with total availability at $119.5 million, taking into account $0.5 million in face amount of letters of credit issued under the sub-facility. The current weighted average interest rate for all debt is 4.6%.
Among its affirmative covenants, the credit agreement governing this credit facility requires the Company to maintain the following consolidated ratios (as defined and calculated according to the credit agreement) as of the end of each fiscal quarter:
(a) “Total Leverage Ratio” less than or equal to 3.50 to 1.00.
(b) “Interest Coverage Ratio” greater than or equal to 3.00 to 1.00.

As of June 30, 2019, the Company was in full compliance with all debt covenant requirements.

Page 19 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Based on $180.0 million outstanding borrowings as floating rate debt, an immediate increase of one percentage point would cause an increase to interest expense of approximately $1.8 million per year.
Total interest paid by the Company for all indebtedness for the six months ended June 30, 2019 and June 30, 2018 was $7.6 million and $6.8 million, respectively.
 
Interest expense, net consists of the following:
 
 
Three months ended
 
Six months ended
 
June 30,
2019
 
June 30,
2018
 
June 30,
2019
 
June 30,
2018
Interest expense
$
3,924

 
$
3,482

 
$
7,624

 
$
6,578

Deferred financing cost
108

 
107

 
215

 
215

Interest income
(36
)
 
(12
)
 
(63
)
 
(32
)
Less: amount capitalized for capital projects
(109
)
 
(379
)
 
(187
)
 
(659
)
Total interest expense, net
$
3,887

 
$
3,198

 
$
7,589

 
$
6,102


In December 2018, the Company entered into an interest rate swap, swapping the LIBOR exposure of $150.0 million of floating rate debt, which is currently outstanding under our Credit Agreement, to a fixed rate to maturity obligation of 2.677% expiring in November 2021.
The Company manages interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with the credit status.
The table below presents the fair value of the Company's derivative financial instruments as well as their classification in the Consolidated Balance Sheets as of June 30, 2019 and December 31, 2018.

Tabular Disclosure of Fair Values of Derivative Instruments
 
 
 
Fair value as of
Derivatives designated as hedging instruments
Balance Sheet Location
 
June 30,
2019
 
December 31,
2018
Interest Rate Contract
Other Long-Term Liabilities
 
$
3,787

 
$
1,023

 
 
 
$
3,787

 
$
1,023



The table below presents the effect of the Company’s derivative financial instruments in the Consolidated Statements of Operations and AOCI for the three and six months ended June 30, 2019 and June 30, 2018.

Tabular Disclosure of the Effect of Derivative Instruments
 
 
 
 
 
Derivatives in Cash Flow Hedging Relationships
 
Amount of Gain/(Loss) Recognized in AOCI on Derivative
 
Location of Gain/(Loss) Reclassified from AOCI into Income
 
Amount of Gain/(Loss) Reclassified from AOCI into Income
Interest Rate Contract
 
$
(1,862
)
 
Interest Income/(Expense)
 
$
(77
)
Three months ended June 30, 2019
 
$
(1,862
)
 
 
 
$
(77
)
 
 
 
 
 
 
 
Interest Rate Contract
 
$
(2,763
)
 
Interest Income/(Expense)
 
$
(140
)
Six months ended June 30, 2019
 
$
(2,763
)
 
 
 
$
(140
)
 
 
 
 
 
 
 
Interest Rate Contract
 
$

 
Interest Income/(Expense)
 
$

Three months ended June 30, 2018
 
$

 
 
 
$

 
 
 
 
 
 
 
Interest Rate Contract
 
$

 
Interest Income/(Expense)
 
$

Six months ended June 30, 2018
 
$

 
 
 
$



Page 20 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)



12. Other Long-Term Liabilities
Other long-term liabilities consist of the following:
 
 
June 30,
2019
 
December 31,
2018
Deferred income taxes
$
8,570

 
$
5,113

Pension and post retirement liabilities
9,632

 
9,238

Uncertain tax positions
320

 
320

Environmental liabilities
1,100

 
1,100

Deferred gain on sale leaseback transaction (a)

 
15,073

Deferred contract termination fee (b)
10,425

 
15,371

Interest rate hedge
3,787

 
1,023

Other liabilities
2,366

 
2,401

 
$
36,200

 
$
49,639


(a) See Note 8 to the Consolidated Financial Statements for further details.
(b) See Note 18 to the Consolidated Financial Statements for further details.


13. Income Taxes
The effective income tax rate on income before taxes was approximately 58% for the six months ended June 30, 2019 compared to approximately 28% for the comparable period in 2018. The change in the effective tax rate is primarily due to the Dutch tax matter described below.
In the second quarter of 2019, the Company incurred a Dutch income tax liability of $6.6 million which was recorded in current liabilities. See Note 14 for further information.
Business is conducted in various countries throughout the world and is subject to tax in numerous jurisdictions. A significant number of tax returns are filed and subject to examination by various federal, state and local tax authorities. Tax examinations are often complex, as tax authorities may disagree with the treatment of items reported requiring several years to resolve. As such, the Company maintains liabilities for possible assessments by tax authorities resulting from known tax exposures for uncertain income tax positions. The Company’s policy is to accrue associated penalties in selling, general and administrative expenses and to accrue interest in net interest expense. Currently, the Company is under examination, or has been contacted for examination on income tax returns, for the years 2014 through 2017. During the quarter ended June 30, 2019, the Company's liability for unrecognized tax benefits was unchanged. The Company estimates the liability for unrecognized tax benefits will not change during the next twelve months. Other than the items mentioned above, as of June 30, 2019, no material adjustments have been proposed to the Company's tax positions and the Company currently does not anticipate any adjustments that would result in a material change to its financial position during the next twelve months.
Income taxes paid were $9.0 million and $12.8 million for the six months ended June 30, 2019 and June 30, 2018, respectively.

14. Commitments and Contingencies
Environmental

The Company's operations are subject to extensive and changing federal, state, local and international environmental laws, rules and regulations. The Company's manufacturing sites have an extended history of industrial use, and soil and groundwater contamination have or may have occurred in the past and might occur or be discovered in the future.


Page 21 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Environmental efforts are difficult to assess for numerous reasons, including the discovery of new remedial sites, discovery of new information and scarcity of reliable information pertaining to certain sites, improvements in technology, changes in environmental laws and regulations, numerous possible remedial techniques and solutions, difficulty in assessing the involvement of and the financial capability of other potentially responsible parties and the extended time periods over which remediation occurs. Other than the items listed below, the Company is not aware of material environmental liabilities which are probable and estimable. As the Company's environmental contingencies are more clearly determined, it is reasonably possible that amounts may need to be accrued. However, management does not believe, based on current information, that environmental remediation requirements will have a material impact on the Company's results of operations, financial position or cash flows.
Future environmental spending is probable at the Company's site in Nashville, Tennessee, the eastern portion of which had been used historically as a landfill, and a western parcel therein, previously acquired from a third party, which reportedly had housed, but no longer does, a fertilizer and pesticide manufacturing facility. The Company has an estimated liability with a range of $0.9 million-$1.3 million. The remedial action plan for that site has yet to be finalized, and as such, the Company has recorded a liability, which represents the Company's best estimate, of $1.1 million as of June 30, 2019.
Litigation

In 2018, following a review of its global corporate and financing structure, Innophos’ management initiated a global entity simplification plan which included a strategy to merge two of the Company’s Dutch subsidiaries by the end of 2018. The contemplated merger was not completed in 2018 due to an administrative error committed and acknowledged by the Company’s Dutch legal counsel, Heussen B.V ("Heussen"). Such merger was ultimately completed in 2019. On May 17, 2019, changes to Dutch tax law were enacted and as expected, with retroactive effect to January 1, 2018. As a result of these changes in Dutch tax law and the merger of the two Dutch subsidiaries not completed in 2018, the Company incurred in its second quarter 2019 results a Dutch corporate income tax liability of $6.6 million for its 2018 tax year. On July 23, 2019, the Company initiated a malpractice legal proceeding in the Netherlands against Heussen seeking reimbursement for all costs and liabilities resulting from their administrative error, including all related tax liabilities and other associated expenses and damages. Any recovery by the Company in respect of that proceeding will be recorded gross in the period it is received.

In addition, the Company is a party to legal proceedings and contractual disputes that arise in the ordinary course of its business. Except as to the matters specifically discussed, management believes the likelihood that the ultimate disposition of these matters will have a material adverse effect on the Company's business, results of operations, financial condition and/or cash flows is remote. However, these matters cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on the Company's business, results of operations, financial condition, and/or cash flows.


Page 22 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

15. Pension Plans and Postretirement Benefits

Net periodic benefit expense for the United States plans:

Three months ended June 30, 2019
 
Three months ended June 30, 2018
 
Pension benefits
 
Other benefits
 
Total
 
Pension benefits
 
Other benefits
 
Total
Service cost
$

 
$
36

 
$
36

 
$

 
$
37

 
$
37

Interest cost
26

 
34

 
60

 
23

 
29

 
52

Expected return on assets
(39
)
 

 
(39
)
 
(37
)
 

 
(37
)
Amortization of
 
 
 
 
 
 
 
 
 
 
 
prior service cost

 

 

 

 

 

unrecognized (gain) loss

 
(39
)
 
(39
)
 

 
(40
)
 
(40
)
net transition obligation

 

 

 

 

 

Net periodic (benefit) cost
$
(13
)
 
$
31

 
$
18

 
$
(14
)
 
$
26

 
$
12

 
 
 
 
 
 
 
 
 
 
 
 
 
Six Months Ended June 30, 2019
 
Six Months Ended June 30, 2018
 
Pension benefits
 
Other benefits
 
Total
 
Pension benefits
 
Other benefits
 
Total
Service cost
$

 
$
72

 
$
72

 
$

 
$
73

 
$
73

Interest cost
51

 
68

 
119

 
47

 
58

 
105

Expected return on assets
(79
)
 

 
(79
)
 
(75
)
 

 
(75
)
Amortization of
 
 
 
 
 
 
 
 
 
 
 
prior service cost

 

 

 

 

 

unrecognized (gain) loss

 
(78
)
 
(78
)
 

 
(80
)
 
(80
)
net transition obligation

 

 

 

 

 

Net periodic cost
$
(28
)
 
$
62

 
$
34

 
$
(28
)
 
$
51

 
$
23


Innophos has no minimum contribution requirements and does not plan to make cash contributions for its U.S. defined benefit pension plan in 2019.
Innophos had no minimum contribution requirements and did not make cash contributions for its U.S. defined benefit pension plan in 2018.


Page 23 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Net periodic benefit expense for the Canadian plans:
 
Three months ended June 30, 2019
 
Three months ended June 30, 2018
 
Pension benefits
 
Other benefits
 
Total
 
Pension benefits
 
Other benefits
 
Total
Service cost
$
97

 
$
15

 
$
112

 
$
109

 
$
16

 
$
125

Interest cost
137

 
15

 
152

 
129

 
14

 
143

Expected return on assets
(205
)
 

 
(205
)
 
(198
)
 

 
(198
)
Amortization of
 
 
 
 
 
 
 
 
 
 
 
actuarial loss (gain)
52

 

 
52

 
47

 
1

 
48

prior service cost
13

 

 
13

 
13

 

 
13

net transition obligation

 
3

 
3

 

 
6

 
6

Exchange rate changes
(79
)
 
29

 
(50
)
 
100

 
(34
)
 
66

Net periodic cost (benefit)
$
15

 
$
62

 
$
77

 
$
200

 
$
3

 
$
203

 
 
 
 
 
 
 
 
 
 
 
 
 
Six Months Ended June 30, 2019
 
Six Months Ended June 30, 2018
 
Pension benefits
 
Other benefits
 
Total
 
Pension benefits
 
Other benefits
 
Total
Service cost
$
190

 
$
30

 
$
220

 
$
222

 
$
32

 
$
254

Interest cost
268

 
30

 
298

 
261

 
29

 
290

Expected return on assets
(403
)
 

 
(403
)
 
(403
)
 

 
(403
)
Amortization of
 
 
 
 
 
 
 
 
 
 
 
actuarial loss (gain)
102

 

 
102

 
95

 
2

 
97

prior service cost
25

 

 
25

 
26

 

 
26

net transition obligation

 
6

 
6

 

 
12

 
12

Exchange rate changes
(167
)
 
59

 
(108
)
 
218

 
(73
)
 
145

Net periodic cost
$
15

 
$
125

 
$
140

 
$
419

 
$
2

 
$
421


Innophos Canada, Inc. plans to make cash contributions to its Canadian defined benefit plan of approximately $0.3 million in 2019.
Innophos Canada, Inc. made cash contributions to its Canadian defined benefit plan of approximately $0.7 million in 2018.

Page 24 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)



16. Accumulated Other Comprehensive Income (Loss)
Changes in accumulated other comprehensive income (loss) by component:
Three months ended June 30, 2019
Pension and Other Postretirement Adjustments
 
Changes in Fair Value of Effective Cash Flow Hedges
 
Total
Balance at March 31, 2019
$
(2,301
)
 
$
(1,443
)
 
$
(3,744
)
Other comprehensive (loss) before reclassifications

 
(1,455
)
 
(1,455
)
Amounts reclassified from accumulated other comprehensive income
(662
)
 
58

 
(604
)
Net current period other comprehensive (loss)
(662
)
 
(1,397
)
 
(2,059
)
Balance at June 30, 2019
$
(2,963
)
 
$
(2,840
)
 
$
(5,803
)
 
 
 
 
 
 
Three months ended June 30, 2018
Pension and Other Postretirement Adjustments
 
Changes in Fair Value of Effective Cash Flow Hedges
 
Total
Balance at March 31, 2018
$
(1,809
)
 
$

 
$
(1,809
)
Other comprehensive income before reclassifications
94

 

 
94

Amounts reclassified from accumulated other comprehensive income

 

 

Net current period other comprehensive income
94

 

 
94

Balance at June 30, 2018
$
(1,715
)
 
$

 
$
(1,715
)
 
 
 
 
 
 
 
 
 
 
 
 
Six months ended June 30, 2019
Pension and Other Postretirement Adjustments
 
Changes in Fair Value of Effective Cash Flow Hedges
 
Total
Balance at December 31, 2018
$
(2,249
)
 
$
(767
)
 
$
(3,016
)
Other comprehensive (loss) before reclassifications

 
(2,178
)
 
(2,178
)
Amounts reclassified from accumulated other comprehensive income
(714
)
 
105

 
(609
)
Net current period other comprehensive (loss)
(714
)
 
(2,073
)
 
(2,787
)
Balance at June 30, 2019
$
(2,963
)
 
$
(2,840
)
 
$
(5,803
)
 
 
 
 
 
 
Six months ended June 30, 2018
Pension and Other Postretirement Adjustments
 
Changes in Fair Value of Effective Cash Flow Hedges
 
Total
Balance at December 31, 2017
$
(2,198
)
 
$

 
$
(2,198
)
Other comprehensive income before reclassifications
190

 

 
190

Amounts reclassified from accumulated other comprehensive income
293

 

 
293

Net current period other comprehensive income
483

 

 
483

Balance at June 30, 2018
$
(1,715
)
 
$

 
$
(1,715
)



Page 25 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


17. Segment Reporting
The Company discloses certain financial and supplementary information about its reportable segments, revenue by products and revenues by geographic area. Operating segments are defined as components of an enterprise about which separate discrete financial information is evaluated regularly by the chief operating decision maker, in order to decide how to allocate resources and assess performance. The primary performance indicators for the chief operating decision maker are sales and EBITDA (defined as net income (loss) before interest, income taxes, depreciation and amortization). All references to sales in this Quarterly Report on Form 10-Q are recognized when title and risk of loss passes to the customer, which occurs either upon shipment or delivery, depending upon the agreed sales terms with customers.
The Company's chief executive officer is the chief operating decision maker and has determined to assess the Company's performance and allocate the appropriate resources based on the following operating segments: (1) Food, Health and Nutrition; (2) Industrial Specialties; and (3) Other. These reporting segments accurately reflect the underlying business dynamics and align with the strategic direction of the Company.

During the second quarter of 2019, the Company adjusted the EBITDA allocation for certain transactions to align it with the underlying business. As a result, EBITDA in the Other segment decreased by $1.4 million with corresponding increases to Food, Health and Nutrition of $1.0 million and Industrial Specialties of $0.4 million.
Three months ended June 30, 2019
 
Food, Health and Nutrition
 
Industrial Specialties
 
Other
 
Total
Net sales
 
$
106,543


$
67,725


$
10,770


$
185,038

EBITDA
 
$
19,561


$
6,972


$
(270
)

$
26,263

Depreciation and amortization expense
 
$
6,781


$
3,766


$
339


$
10,886

 
 
 
 
 
 
 
 
 
Three months ended June 30, 2018
 
Food, Health and Nutrition
 
Industrial Specialties
 
Other
 
Total
Net sales
 
$
125,664

 
$
66,751

 
$
14,310

 
$
206,725

EBITDA
 
$
14,939

 
$
7,794

 
$
(223
)
 
$
22,510

Depreciation and amortization expense
 
$
7,213

 
$
3,368

 
$
508

 
$
11,089

 
 
 
 
 
 
 
 
 
Six months ended June 30, 2019
 
Food, Health and Nutrition
 
Industrial Specialties
 
Other
 
Total
Net sales
 
$
221,609

 
$
130,923

 
$
23,920

 
$
376,452

EBITDA
 
$
33,967

 
$
15,029

 
$
3,041

 
$
52,037

Depreciation and amortization expense
 
$
13,169

 
$
6,946

 
$
531

 
$
20,646

 
 
 
 
 
 
 
 
 
Six months ended June 30, 2018
 
Food, Health and Nutrition
 
Industrial Specialties
 
Other
 
Total
Net sales
 
$
252,027

 
$
130,101

 
$
30,037

 
$
412,165

EBITDA
 
$
33,931

 
$
17,886

 
$
564

 
$
52,381

Depreciation and amortization expense
 
$
14,535

 
$
7,104

 
$
814

 
$
22,453



Page 26 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

A reconciliation of net income to EBITDA follows:
 
 
Three months ended
 
 
June 30,
2019
 
June 30,
2018
Net income
 
$
1,401

 
$
6,246

Provision for income taxes
 
10,089

 
1,977

Interest expense, net
 
3,887

 
3,198

Depreciation and amortization
 
10,886

 
11,089

EBITDA
 
$
26,263

 
$
22,510

 
 
 
 
 
 
 
Six months ended
 
 
June 30,
2019
 
June 30,
2018
Net income
 
$
10,095

 
$
17,161

Provision for income taxes
 
13,707

 
6,665

Interest expense, net
 
7,589

 
6,102

Depreciation and amortization
 
20,646

 
22,453

EBITDA
 
$
52,037

 
$
52,381




Page 27 of 43



INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES
Notes to Condensed Consolidated Financial Statements (Unaudited)
(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)


18. Supply Agreement Termination
    
In June 2018, the Company agreed to terminate a previously long-term supply agreement and replaced it with a short-term agreement. In December 2018, as a result of the termination, the Company received consideration of $24.9 million which included $21.3 million in cash as well as receipt of certain tangible assets with a fair value of $3.6 million. The consideration was recorded as a deferred liability with $9.5 million in Other current liabilities and the remaining $15.4 million recorded in Other long-term liabilities. Beginning in January 2019, the deferred liability is being amortized on a straight-line basis through July 2021, which is the end of the new supply agreement, as a reduction of Cost of goods sold. For the three and six months ended June 30, 2019 amortization of the deferred liability was $2.4 million and $4.8 million, respectively.

ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Innophos is a leading international producer of specialty ingredient solutions that deliver versatile benefits for the food, health, nutrition and industrial markets. Innophos combines more than a century of experience in specialty phosphate manufacturing with a broad range of other specialty nutritional ingredients. Many of Innophos' products are application-specific compounds engineered to meet customer performance requirements and are often critical to the taste, texture and performance of foods, beverages, pharmaceuticals, oral care products and other applications. For example, Innophos products act as flavor enhancers in beverages, electrolytes in sports drinks, texture additives in cheeses, leavening agents in baked goods, pharmaceutical excipients, cleaning agents in toothpaste, and they also provide a wide range of nutritional fortification solutions for food, beverage and nutritional supplement manufacturers.

Recent Trends and Outlook

Revenues are now forecasted to be 6-7% below 2018 revenue of $802 million, compared with the prior expectation of 1-2% down.

The revised revenue range reflects the expectation that the U.S. fertilizer sales impacted by Midwest flooding will not rebound in 2019 as previously expected. In addition, the Company expects market softness to continue to impact both the Food, Health and Nutrition segment and the Industrial Specialties segment volumes, as well as Industrial Specialties segment pricing and volumes to continue to be affected indirectly by tariffs. These factors will be partially offset by positive year-over-year revenue contribution from price increases and new product wins. The year-over-year volume decline from the discontinuation of the low margin nutrition business is expected to impact comps through the end of the year, but less materially for the fourth quarter.

From a GAAP and cash flow perspective, costs are expected to be lower in H2 than H1 as the Company winds down spending on the non-recurring expenses that are adjusted for non-GAAP reporting purposes, including value chain transition expense and Mexico natural gas supply adjustment charges.

Capital investments are now expected to be in the $45 to $50 million range, approximately 15-20% below 2018 spending. This compares with the prior expectation of capital investments in line with prior year, and reflects the Company’s expectation to be more efficient with spending to finalize the optimization of the value chain and manufacturing program while continuing to make investments in high return projects.

The Company expects its effective tax rate to operate in the 28-32% range, excluding the second quarter $6.6 million one-time Dutch tax charge.





Page 28 of 43



Table of Contents


Results of Operations
The following table sets forth a summary of the Company’s operations and their percentages of total revenue for the periods indicated (dollars in millions):
 
 
Three Months Ended
 
June 30, 2019
 
June 30, 2018
 
Amount
 
%
 
Amount
 
%
Net sales
$
185.0

 
100.0

 
$
206.7

 
100.0

Cost of goods sold
148.6

 
80.3

 
170.3

 
82.4

Gross profit
36.4

 
19.7

 
36.4

 
17.6

Operating expenses:
 
 
 
 
 
 
 
Selling, general and administrative
20.3

 
11.0

 
22.5

 
10.9

Research & development
1.2

 
0.6

 
1.4

 
0.7

Income from operations
14.9

 
8.1

 
12.5

 
6.0

Interest expense, net
3.9

 
2.1

 
3.2

 
1.5

Foreign exchange (gain) loss, net
(0.5
)
 
(0.3
)
 
1.1

 
0.5

Provision for income taxes
10.1

 
5.5

 
2.0

 
1.0

Net income
$
1.4

 
0.8

 
$
6.2

 
3.0

 
 
 
 
 
 
 
 
 
Six Months Ended
 
June 30, 2019
 
June 30, 2018
 
Amount
 
%
 
Amount
 
%
Net sales
$
376.5

 
100.0

 
$
412.2

 
100.0

Cost of goods sold
303.7

 
80.7

 
333.6

 
80.9

Gross profit
72.8

 
19.3

 
78.6

 
19.1

Operating expenses:
 
 
 
 
 
 
 
Selling, general and administrative
39.7

 
10.5

 
45.0

 
10.9

Research & development
2.6

 
0.7

 
2.8

 
0.6

Income from operations
30.5

 
8.1

 
30.8

 
7.5

Interest expense, net
7.6

 
2.0

 
6.1

 
1.5

Foreign exchange (gain) loss, net
(0.9
)
 
(0.2
)
 
0.9

 
0.2

Provision for income taxes
13.7

 
3.6

 
6.6

 
1.7

Net income
$
10.1

 
2.7

 
$
17.2

 
4.2




Page 29 of 43



Table of Contents

Three months ended June 30, 2019 compared to the three months ended June 30, 2018
Net Sales
Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items invoiced to customers. Net sales for the three months ended June 30, 2019 were $185.0 million, a decrease of $21.7 million, or 10.5%, as compared to $206.7 million for the same period in 2018, with prices up 2.9%, and volumes lower by 13.4%. Food, Health and Nutrition segment sales were down 15.2%, or $19.1 million, with selling prices higher by 3.1%, or $3.8 million, but volumes lower by 18.3%, or $22.9 million. Industrial Specialties segment sales were up 1.5%, or $1.0 million, with volumes lower by 1.9%, or $1.3 million, but selling prices higher by 3.4%, or $2.3 million. Other segment sales were lower by 24.7%, or $3.6 million, with volumes lower by 23.4%, or $3.4 million, and selling prices lower by 1.3%, or $0.2 million.
The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix.
The following table illustrates for the three months ended June 30, 2019 the percentage changes in net sales by reportable segment compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:
 
 
Price
 
Volume/Mix
 
Total
Food, Health and Nutrition
3.1
 %
 
(18.3
)%
 
(15.2
)%
Industrial Specialties
3.4
 %
 
(1.9
)%
 
1.5
 %
Other
(1.3
)%
 
(23.4
)%
 
(24.7
)%
Total
2.9
 %
 
(13.4
)%
 
(10.5
)%

Gross Profit
Gross profit represents net sales less cost of goods sold. Gross profit for the three months ended June 30, 2019 was $36.4 million, flat with the same period in 2018. Gross profit as a percentage of net sales increased to 19.7% for the three months ended June 30, 2019 versus 17.6% for the same period in 2018.

The following table outlines the factors resulting in the year on year change in the three months ended June 30, 2019.
 
$ (in millions)
Higher selling prices
$
5.9

Lower sales volume/mix
(6.5
)
Supply agreement termination amortization
2.4

Severance
(0.3
)
Higher raw materials costs (a)
(0.1
)
Higher manufacturing cost (a)
(4.8
)
Lower value chain transition costs
3.4

Higher depreciation and amortization (a)
(0.9
)
Lower turnaround cost at our Coatzacoalcos, Mexico manufacturing facility
0.9

 
$


(a) For the three months ended June 30, 2019, includes a $3.1 million benefit related to a cumulative adjustment of capitalized variances.





Page 30 of 43



Table of Contents

Operating Expenses and Research and Development
Operating expenses consist primarily of selling, general and administrative and research and development expenses. Operating expenses for the three months ended June 30, 2019 were $21.5 million, a decrease of $2.4 million, or 10.0%, as compared to $23.9 million for the same period in 2018. The decrease was primarily due to $1.1 million lower depreciation and $2.6 million lower administration costs from acquisition synergies, partially offset by $0.8 million higher non-cash stock compensation expense and $0.7 million higher severance expense.
Operating Income
Operating income for the three months ended June 30, 2019 was $14.9 million, an increase of $2.4 million, or 19.2%, as compared to $12.5 million for the same period in 2018. Operating income as a percentage of net sales increased to 8.1% versus 6.0% for the same period in 2018, for the reasons noted above.
Interest Expense, net
Net interest expense, including deferred financing amortization expense, for the three months ended June 30, 2019 was $3.9 million, an increase of $0.7 million, or 21.9%, as compared to $3.2 million for the same period in 2018. The increase was primarily due to higher market interest rates and lower capitalized interest.
Foreign Exchange
Foreign exchange for the three months ended June 30, 2019 was a gain of $0.5 million as compared to a loss of $1.1 million for the same period in 2018. The U.S. Dollar is the functional currency of our Mexican and Canadian operations. The Company has greater foreign denominated asset balances (largely Mexican Peso and Canadian Dollar), such as VAT receivables and prepaid income taxes in foreign jurisdictions, than offsetting foreign denominated liability balances. Foreign exchange gain or loss is recorded on remeasurement of non-U.S. Dollar denominated monetary assets and liabilities. Such gains and losses fluctuate from period to period as the foreign currencies strengthen or weaken against the U.S. Dollar and the amount of non-U.S. Dollar denominated assets and liabilities increases or decreases.
Provision for Income Taxes
The effective income tax rate on income before taxes was approximately 88% for the three months ended June 30, 2019 compared to approximately 24% for the comparable period in 2018.The change in the effective tax rate is primarily due to the Dutch tax matter (Note 14).
Net Income
Net income for the three months ended June 30, 2019 was $1.4 million, as compared to $6.2 million for the same period in 2018, due to the factors described above.
 

Six months ended June 30, 2019 compared to the six months ended June 30, 2018

Net Sales
Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items invoiced to customers. Net sales for the six months ended June 30, 2019 were $376.5 million, a decrease of $35.7 million, or 8.7%, as compared to $412.2 million for the same period in 2018, with prices up 3.3%, and volumes lower by 12.0%. Food, Health and Nutrition segment sales were down 12.1%, or $30.4 million, with selling prices higher by 3.7%, or $9.4 million, but volumes lower by 15.8%, or $39.8 million. Industrial Specialties segment sales were up 0.6%, or $0.8 million, with volumes lower by 2.9%, or $3.7 million, but selling prices higher by 3.5%, or $4.5 million. Other segment sales were lower by 20.4%, or $6.1 million, with volumes lower by 19.3%, or $5.8 million, and selling prices lower by 1.1%, or $0.3 million.
The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix.
The following table illustrates for the six months ended June 30, 2019 the percentage changes in net sales by reportable segment compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:
 

Page 31 of 43



Table of Contents

 
Price
 
Volume/Mix
 
Total
Food, Health and Nutrition
3.7
 %
 
(15.8
)%
 
(12.1
)%
Industrial Specialties
3.5
 %
 
(2.9
)%
 
0.6
 %
Other
(1.1
)%
 
(19.3
)%
 
(20.4
)%
Total
3.3
 %
 
(12.0
)%
 
(8.7
)%

Gross Profit
Gross profit represents net sales less cost of goods sold. Gross profit for the six months ended June 30, 2019 was $72.8 million, a decrease of $5.8 million, or 7.4%, as compared to $78.6 million for the same period in 2018. Gross profit as a percentage of net sales increased to 19.3% for the six months ended June 30, 2019 versus 19.1% for the same period in 2018.

The following table outlines the factors resulting in the year on year change in the six months ended June 30, 2019.
 
$ (in millions)
Higher selling prices
$
13.6

Lower sales volume/mix
(13.0
)
Supply agreement termination amortization
4.8

Severance
(0.5
)
Higher raw materials costs (a) (b)
(5.1
)
Higher manufacturing cost (b)
(6.8
)
Lower value chain transition costs
1.8

Higher depreciation and amortization (b)
(0.3
)
Higher natural gas cost at our Coatzacoalcos, Mexico manufacturing facility
(1.2
)
Lower turnaround cost at our Coatzacoalcos, Mexico manufacturing facility
0.9

 
$
(5.8
)
(a) Primarily sulfur and MGA.
(b) For the six months ended June 30, 2019, includes a $3.1 million benefit related to a cumulative adjustment of capitalized variances.

Operating Expenses and Research and Development
Operating expenses consist primarily of selling, general and administrative and research and development expenses. Operating expenses for the six months ended June 30, 2019 were $42.3 million, a decrease of $5.5 million, or 11.5%, as compared to $47.8 million for the same period in 2018. The decrease was primarily due to $2.2 million lower depreciation and $4.6 million lower administration costs from acquisition synergies, partially offset by $1.4 million higher severance expense.
Operating Income
Operating income for the six months ended June 30, 2019 was $30.5 million, a decrease of $0.3 million, or 1.0%, as compared to $30.8 million for the same period in 2018. Operating income as a percentage of net sales increased to 8.1% versus 7.5% for the same period in 2018, for the reasons noted above.
Interest Expense, net
Net interest expense, including deferred financing amortization expense, for the six months ended June 30, 2019 was $7.6 million, an increase of $1.5 million, or 24.6%, as compared to $6.1 million for the same period in 2018. The increase was primarily due to higher market interest rates and lower capitalized interest.
Foreign Exchange
Foreign exchange for the six months ended June 30, 2019 was a gain of $0.9 million as compared to a loss of $0.9 million for the same period in 2018. The U.S. Dollar is the functional currency of our Mexican and Canadian operations. The Company has greater foreign denominated asset balances (largely Mexican Peso and Canadian Dollar), such as VAT receivables and prepaid income taxes in foreign jurisdictions, than offsetting foreign denominated liability balances. Foreign exchange gain or loss is recorded on remeasurement of non-U.S. Dollar denominated monetary assets and liabilities. Such

Page 32 of 43



Table of Contents

gains and losses fluctuate from period to period as the foreign currencies strengthen or weaken against the U.S. Dollar and the amount of non-U.S. Dollar denominated assets and liabilities increases or decreases.
Provision for Income Taxes
The effective income tax rate on income before taxes was approximately 58% for the six months ended June 30, 2019 compared to approximately 28% for the comparable period in 2018. The change in the effective tax rate is primarily due to the Dutch tax matter (Note 14).
Net Income
Net income for the six months ended June 30, 2019 was $10.1 million, as compared to $17.2 million for the same period in 2018, due to the factors described above.
 



Page 33 of 43



Table of Contents

Segment Reporting
The Company's chief executive officer is the chief operating decision maker and has determined to assess the Company's performance and allocate the appropriate resources based on the following operating segments: (1) Food, Health and Nutrition; (2) Industrial Specialties; and (3) Other. These reporting segments accurately reflect the underlying business dynamics and align with the strategic direction of the Company. The primary performance indicators for the chief operating decision maker are sales and earnings before interest, taxes, depreciation and amortization, or EBITDA. The following table sets forth the results of these indicators by segment for the three and six months ended June 30, 2019 and June 30, 2018:
 

Three Months Ended



June 30,
2019
 
June 30,
2018

Net Sales % Change
Segment Net Sales





Food, Health and Nutrition
$
106,543


$
125,664


(15.2
)%
Industrial Specialties
67,725


66,751


1.5
 %
Other
10,770


14,310


(24.7
)%
Total
$
185,038


$
206,725


(10.5
)%






Segment EBITDA





Food, Health and Nutrition
$
19,561

 
$
14,939




Industrial Specialties
6,972

 
7,794




Other
(270
)
 
(223
)



Total
$
26,263


$
22,510










Segment EBITDA % of net sales





Food, Health and Nutrition
18.4
 %

11.9
 %



Industrial Specialties
10.3
 %

11.7
 %



Other
(2.5
)%

(1.6
)%



Total
14.2
 %

10.9
 %









Depreciation and amortization expense





Food, Health and Nutrition
$
6,781

 
$
7,213




Industrial Specialties
3,766

 
3,368




Other
339

 
508




Total
$
10,886


$
11,089






Page 34 of 43



Table of Contents

 
 
 
 
 
 
 
Six Months Ended
 
 
 
June 30,
2019

June 30,
2018
 
Net Sales % Change
Segment Net Sales
 
 
 
 
 
Food, Health and Nutrition
$
221,609

 
$
252,027

 
(12.1
)%
Industrial Specialties
130,923

 
130,101

 
0.6
 %
Other
23,920

 
30,037

 
(20.4
)%
Total
$
376,452

 
$
412,165

 
(8.7
)%
 
 
 
 
 
 
Segment EBITDA
 
 
 
 
 
Food, Health and Nutrition
$
33,967

 
$
33,931

 
 
Industrial Specialties
15,029

 
17,886

 
 
Other
3,041

 
564

 
 
Total
$
52,037

 
$
52,381

 
 
 
 
 
 
 
 
Segment EBITDA % of net sales
 
 
 
 
 
Food, Health and Nutrition
15.3
%
 
13.5
%
 
 
Industrial Specialties
11.5
%
 
13.7
%
 
 
Other
12.7
%
 
1.9
%
 
 
Total
13.8
%
 
12.7
%
 
 
 
 
 
 
 
 
Depreciation and amortization expense
 
 
 
 
 
Food, Health and Nutrition
$
13,169

 
$
14,535

 
 
Industrial Specialties
6,946

 
7,104

 
 
Other
531

 
814

 
 
Total
$
20,646

 
$
22,453

 
 
A reconciliation of net income to EBITDA follows:


Three months ended


June 30,
2019
 
June 30,
2018
Net income

$
1,401

 
$
6,246

Provision for income taxes

10,089

 
1,977

Interest expense, net

3,887

 
3,198

Depreciation and amortization

10,886

 
11,089

EBITDA

$
26,263


$
22,510

 
 
Six Months Ended
 
 
June 30,
2019
 
June 30,
2018
Net income
 
$
10,095

 
$
17,161

Provision for income taxes
 
13,707

 
6,665

Interest expense, net
 
7,589

 
6,102

Depreciation and amortization
 
20,646

 
22,453

EBITDA
 
$
52,037

 
$
52,381



Page 35 of 43



Table of Contents

Three months ended June 30, 2019 compared to the three months ended June 30, 2018
Segment Net Sales:
Food, Health and Nutrition net sales decreased 15.2% for the three months ended June 30, 2019 compared with the same period in 2018. Volumes decreased 18.3%, due to the Company's decision to discontinue low-margin nutrition trading business and softer demand including customer destocking. Average selling price increased 3.1%.
Industrial Specialties net sales increased 1.5% for the three months ended June 30, 2019 compared with the same period in 2018. Volumes decreased 1.9%, but average selling prices increased by 3.4%.
Other net sales decreased 24.7% for the three months ended June 30, 2019 compared with the same period in 2018. Volumes decreased 23.4% due primarily to reduced co-product and low grade acid sales, and average selling prices decreased 1.3%.
Segment EBITDA Percentage of Net Sales:

The 650 basis point increase in Food, Health and Nutrition EBITDA margins for the three months ended June 30, 2019 compared with the same period in 2018 is due to lower raw material costs, largely sulfur and MGA, which increased margins by 340 basis points, higher average selling prices which increased margins by 260 basis points, lower value chain transition costs which increased margins by 180 basis points, lower operating costs which increased margins by 130 basis points, and supply agreement termination amortization (Note 18) which increased margins by 100 basis points. This increase was partially offset by higher manufacturing costs which decreased margins by 250 basis points, lower sales volume/mix which decreased margins by 80 basis points, and other items which decreased margins by 30 basis points.

The 140 basis point decrease in Industrial Specialties EBITDA margins for the three months ended June 30, 2019 compared with the same period in 2018 is due to higher manufacturing and operating costs which decreased margins by 400 basis points, lower sales volume/mix which decreased margins by 340 basis points, and higher raw material costs which decreased margins by 320 basis points. This decrease was partially offset by higher average selling prices which increased margins by 290 basis points, favorable translation which increased margins by 240 basis points, value chain transition costs which increased margins by 200 basis points, supply agreement termination amortization which increased margins by 140 basis points, and other items which increased margins by 50 basis points.

The 90 basis point decrease in Other EBITDA margins for the three months ended June 30, 2019 compared with the same period in 2018 is due to higher raw material costs which decreased margins by 1,530 basis points, lower selling prices which decreased margins 130 basis points, and other items which decreased margins by 20 basis points. This decrease was partially offset by higher sales volume/mix which increased margins by 810 basis points, lower manufacturing and operating costs which increased margins 510 basis points, supply agreement termination amortization which increased margins by 170 basis points, and value chain transition costs which increased margins by 100 basis points.


Six months ended June 30, 2019 compared to the six months ended June 30, 2018
Segment Net Sales:
Food, Health and Nutrition net sales decreased 12.1% for the six months ended June 30, 2019 compared with the same period in 2018. Volumes decreased 15.8%, due to the Company's decision to discontinue low-margin nutrition trading business and softer demand including customer destocking. Average selling price increased 3.7%.
Industrial Specialties net sales increased 0.6% for the six months ended June 30, 2019 compared with the same period in 2018. Volumes decreased 2.9%, but average selling prices increased by 3.5%.
Other net sales decreased 20.4% for the six months ended June 30, 2019 compared with the same period in 2018. Volumes decreased 19.3% due primarily to reduced co-product and low grade acid sales volumes, and average selling prices decreased 1.1%.

Page 36 of 43



Table of Contents

Segment EBITDA Percentage of Net Sales:

The 180 basis point increase in Food, Health and Nutrition EBITDA margins for the six months ended June 30, 2019 compared with the same period in 2018 is due to higher average selling prices which increased margins by 310 basis points, lower operating costs which increased margins by 160 basis points, supply agreement termination amortization which increased margins by 100 basis points, value chain transition costs which increased margins by 50 basis points, and other items which increased margins by 30 basis points. This increase was partially offset by higher manufacturing costs which decreased margins by 230 basis points, lower sales volume/mix which decreased margins by 190 basis points, and higher severance which decreased margins by 50 basis points.

The 220 basis point decrease in Industrial Specialties EBITDA margins for the six months ended June 30, 2019 compared with the same period in 2018 is due to higher manufacturing and operating costs which decreased margins by 370 basis points, higher raw material costs which decreased margins by 200 basis points, lower sales volume/mix which decreased margins by 130 basis points, and higher severance which decreased margins by 40 basis points. This decrease was partially offset by higher average selling prices which increased margins by 290 basis points, supply agreement termination amortization which increased margins by 140 basis points, value chain transition costs which increased margins by 60 basis points, and other items which increased margins by 30 basis points.

The 1,080 basis point increase in Other EBITDA margins for the six months ended June 30, 2019 compared with the same period in 2018 is due to lower manufacturing and operating costs which increased margins 1,140 basis points, favorable translation which increased margins by 570 basis points, higher sales volume/mix which increased margins by 490 basis points, supply agreement termination amortization which increased margins by 160 basis points, lower value chain transition costs and other items which increased margins by 40 basis points. This increase was partially offset by higher raw material costs which decreased margins by 1,050 basis points, higher natural gas costs at our Coatzacoalcos, Mexico manufacturing facility which decreased margins by 120 basis points, lower selling prices which decreased margins 110 basis points, and higher severance which lowered margins by 40 basis points.

Liquidity and Capital Resources
Historical
Our principal liquidity requirements have been, and we expect will be, for working capital and general corporate purposes, including capital expenditures, debt service, and our quarterly dividend program. Currently, the annual dividend payment is $1.92 per share or approximately $38 million. We do not currently have a share repurchase program in place. Capital investments are now expected to be in the $45 to $50 million range, approximately 15-20% below 2018 spending, compared with the prior expectation of in line with prior year, as the Company becomes more efficient with spending to finalize the optimization of the value chain and manufacturing program. We have historically satisfied our liquidity requirements with internally generated cash flows and availability under our revolving credit facility. We expect that our ability to generate cash from our operations and ability to borrow from our credit facilities should be sufficient to support working capital needs, planned growth and capital expenditures for the next 12 months and for the foreseeable future.
Cash Flow Summary
The following table sets forth a summary of the Company’s cash flows for the periods indicated.
 
(Dollars in millions)
Six Months Ended
 
June 30,
2019
 
June 30,
2018
Operating Activities
$
16.8

 
$
9.6

Investing Activities
(15.8
)
 
(26.5
)
Financing Activities
10.9

 
1.0

Effect of foreign exchange rate changes

 
(0.6
)


Page 37 of 43



Table of Contents


Six months ended June 30, 2019 compared to six months ended June 30, 2018
Net cash provided by operating activities was $16.8 million for the six months ended June 30, 2019 compared to $9.6 million for the same period in 2018, an increase in cash of $7.2 million. The increase in operating activities cash largely resulted from lower working capital needs, primarily due to favorable changes in inventories of $20.9 million, accounts receivable of $11.7 million and other current liabilities of $4.9 million, partially offset by an unfavorable change in accounts payable of $21.4 million and other current assets of $8.4 million.
Net cash used for investing activities was $15.8 million for the six months ended June 30, 2019, compared to $26.5 million for the same period in 2018, an increase in cash of $10.7 million. The increase in cash was due to $10.7 million decrease in capital spending.
Approximately 55% of the 2019 capital spending was for strategic growth and cost/productivity improvements and the remaining 45% was for plant maintenance projects.
    Net cash from financing activities for the six months ended June 30, 2019 was a source of $10.9 million, compared to a source of $1.0 million the same period in 2018, an increase in cash of $9.9 million. This increase in cash was primarily due to decreased loan repayments of $34.0 million, partially offset by the decrease in loan borrowings of $24.0 million.
On June 30, 2019, the Company had cash and cash equivalents outside the United States of $25.1 million, or 78% of the Company's balance. The foreign cash amounts are not restricted by law to be used in other countries. The Company's current operating plan does not include any other repatriation of any additional cash and cash equivalents held outside the United States to fund the United States operations. However, in the event we do repatriate cash and cash equivalents held outside of the United States, we may be required to pay additional taxes, such as withholding taxes, to repatriate these funds.

Critical Accounting Estimates and Policies
There have been no material changes from the critical accounting estimates previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.
 
ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are exposed to certain market risks as part of our ongoing business operations. Primary exposures include changes in interest rates, as borrowings under our credit agreement will bear interest at floating rates based on LIBOR plus an applicable borrowing margin. We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status. For fixed-rate debt, interest rate changes do not affect earnings or cash flows. Conversely, for floating-rate debt, interest rate changes generally affect our earnings and cash flows, assuming other factors are held constant.
At June 30, 2019, we had a $450.0 million revolving credit facility, of which $330.0 million of variable-rate debt was outstanding, which approximates fair value (determined using level 2 inputs within the fair value hierarchy). Total remaining availability was $119.5 million, taking into account $0.5 million in face amount of letters of credit issued under the sub-facility. In December 2018, the Company entered into an interest rate swap, swapping the LIBOR exposure of $150.0 million of floating rate debt, which is currently outstanding under our Credit Agreement, to a fixed rate to maturity obligation of 2.677% expiring in November 2021. The fair value of this interest rate swap is a liability of approximately $3.8 million as of June 30, 2019 and is included in other long-term liabilities.
Changes in economic conditions could result in higher interest rates, thereby increasing our interest expense on our revolving line of credit. Changes in economic conditions may also result in lower operating income, reducing our funds available for capital investment, operations or other purposes. In addition, a substantial portion of our operating cash flow and available borrowing capacity on our credit facility has been used to repurchase shares, pay dividends, fund capital expenditures, fund working capital needs and service debt, which may affect our ability to make future acquisitions. We have and may continue to use interest rate protection agreements to minimize our exposure to interest rate fluctuation. Regardless of hedges, we may experience economic loss and a negative impact on earnings or net assets as a result of interest rate fluctuations. Based on $180.0 million outstanding borrowings as floating rate debt, an immediate increase of one percentage point would cause an increase to interest expense of approximately $1.8 million per year.

Page 38 of 43



Table of Contents

We do not currently, but may from time to time, hedge our currency rate and energy risks.
We believe that our concentration of credit risk related to trade accounts receivable is limited since these receivables are spread among a number of customers and are geographically dispersed. No customer accounted for more than 10% of our sales in the last 3 years.
Foreign Currency Exchange Rates
The U.S. Dollar is the functional currency of the Canadian and Mexican operations. Accordingly, these operations’ monetary assets and liabilities are remeasured at current exchange rates, non-monetary assets and liabilities are remeasured at historical exchange rates, and revenue and expenses are remeasured at average exchange rates and at historical exchange rates for the related revenue and expenses of non-monetary assets and liabilities. All transaction gains and losses are included in net income.
Our principal source of exchange rate exposure in our foreign operations consists of expenses, such as labor expenses, which are denominated in the foreign currency of the country in which we operate. A decline in the value of the U.S. Dollar relative to the local currency would generally cause our operational expenses (particularly labor costs) to increase (conversely, a decline in the value of the foreign currency relative to the U.S. Dollar would cause these expenses to decrease). We believe that normal exchange rate fluctuations consistent with recent historical trends would have a modest impact on our expenses, and would not materially affect our financial condition or results of operations. Nearly all of our sales are denominated in U.S. Dollars and our exchange rate exposure in terms of sales revenues is minimal. However, the strength or weakness of the U.S. Dollar versus other currencies can affect our competitiveness in the United States and export markets.
Inflation and changing prices
Our costs and expenses will be subject to inflation and price fluctuations. Significant price fluctuations in raw materials, freight and energy costs, if not compensated for by cost savings from production efficiencies or price increases passed on to customers, could have a material effect on our financial condition and results of operations.
Off-Balance Sheet Arrangements
We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as “structured finance or special purpose entities”, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

Page 39 of 43



Table of Contents


ITEM 4.
CONTROLS AND PROCEDURES
Disclosure Control and Procedures
The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended) that are designed to provide reasonable assurance that information required to be reported in the Company's consolidated financial statements and filings is recorded, processed, summarized and reported within the periods specified in the rules and forms of the Securities and Exchange Commission, or SEC, and that such information is accumulated and communicated to the Company's management, including its Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.
As of June 30, 2019, the Company completed an evaluation under the supervision and with the participation of the Company's management, including the Company's Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based upon that evaluation, the Principal Executive Officer and Principal Financial Officer concluded that the Company's disclosure controls and procedures are effective at the reasonable assurance level.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Changes in Internal Control over Financial Reporting
There have been no changes in our internal control over financial reporting during or with respect to the second quarter of 2019 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Page 40 of 43



Table of Contents


PART II - OTHER INFORMATION
 
ITEM 1.
LEGAL PROCEEDINGS
Note 14 of Notes to Consolidated Condensed Financial Statements in “Part I, Item 1. Financial Statements" contained in this Quarterly Report on Form 10-Q is incorporated herein by reference.
ITEM 1A.
RISK FACTORS
There have been no material changes from the risk factors previously disclosed in our Annual Report on Form 10-K for the year ended December 31, 2018.
ITEM 2.
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The Company did not have any share repurchases on the open market during the second quarter of 2019. From time to time, the Company reacquires shares from employees in connection with the vesting, exercise and forfeiture of awards under its equity compensation plans. In the second quarter of 2019, no such reacquisitions took place.
ITEM 3.
DEFAULTS UPON SENIOR SECURITIES
None.

ITEM 4.
MINE SAFETY DISCLOSURES
None.

ITEM 5.
OTHER INFORMATION
None.

ITEM 6.
EXHIBITS
a) Exhibits. The following exhibits are filed or furnished as part of this report:
Exhibit No.
 
Description
 
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
 
Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
 
Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS
 
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH
 
XBRL Taxonomy Extension Schema Document
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document
*
Not to be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor deemed to be incorporated by reference into any filing under that Act or the Securities Act of 1933, as amended.


Page 41 of 43



Table of Contents

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INNOPHOS HOLDINGS, INC.
 
 
 
/s/ Kim Ann Mink
By:
Kim Ann Mink
Its:
Chief Executive Officer, President and Director
 
(Principal Executive Officer)
 
Dated:
August 8, 2019
 
INNOPHOS HOLDINGS, INC.
 
 
 
/s/ Mark Feuerbach
By:
Mark Feuerbach
Its:
Interim Chief Financial Officer
 
(Principal Financial Officer)
 
Dated:
August 8, 2019


Page 42 of 43



Table of Contents

EXHIBIT INDEX
Exhibit No.
 
Description
31.1
 
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2
 
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*
 
Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*
 
Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS
 
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
101.SCH
 
XBRL Taxonomy Extension Schema Document
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document

*
Not to be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section, nor deemed to be incorporated by reference into any filing under that Act or the Securities Act of 1933, as amended.


Page 43 of 43




Exhibit 31.1
CERTIFICATIONS
I, Kim Ann Mink, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Innophos Holdings, Inc. (“the registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Dated:
August 8, 2019
By:
/S/    KIM ANN MINK        
 
 
 
Kim Ann Mink
 
 
 
Chief Executive Officer, President and Director
(Principal Executive Officer)




Exhibit 31.2
I, Mark Feuerbach, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Innophos Holdings, Inc. (“the registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
Dated:
August 8, 2019
By:
/S/    Mark Feuerbach
 
 
 
Mark Feuerbach
 
 
 
Interim Chief Financial Officer
(Principal Financial Officer)




Exhibit 32.1
Certification Pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350)
I, Kim Ann Mink, certify that:
1. the accompanying Quarterly Report on Form 10-Q for the period ended June 30, 2019 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Innophos Holdings, Inc. at the dates and for the periods indicated.
A signed original of this written statement required by Section 906 has been provided Innophos Holdings, Inc. and will be retained by Innophos Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
The undersigned expressly disclaims any obligation to update the foregoing certification except as required by law.
Date: August 8, 2019
 
/S/    KIM ANN MINK        
Kim Ann Mink
Chief Executive Officer and Director
(Principal Executive Officer)

The foregoing certification is being furnished solely pursuant to the requirements of 18 U.S.C. § 1350 and is not being filed as a part of the Report or as a separate disclosure document.




Exhibit 32.2
Certification Pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350)
I, Mark Feuerbach, certify that:
1. the accompanying Quarterly Report on Form 10-Q for the period ended June 30, 2019 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Innophos Holdings, Inc. at the dates and for the periods indicated.
A signed original of this written statement required by Section 906 has been provided Innophos Holdings, Inc. and will be retained by Innophos Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
The undersigned expressly disclaims any obligation to update the foregoing certification except as required by law.
Date: August 8, 2019
 
/S/  Mark Feuerbach
Mark Feuerbach
Interim Chief Financial Officer
(Principal Financial Officer)

The foregoing certification is being furnished solely pursuant to the requirements of 18 U.S.C. § 1350 and is not being filed as a part of the Report or as a separate disclosure document.